Coates International 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 26, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Entity Registrant Name	'COATES INTERNATIONAL LTD \DE\	'	'
Entity Central Index Key	'0000948426	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Public Float	'	'	$4,210,006
Entity Common Stock, Shares Outstanding	'	342,759,313	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets	'	'
Cash	$49,274	$13,303
Inventory, net	111,752	111,115
Deferred offering costs	12,423	16,207
Total Current Assets	173,449	140,625
Property, plant and equipment, net	2,179,646	2,241,847
Deferred licensing costs, net	51,016	55,299
Total Assets	2,404,111	2,437,771
Current Liabilities	'	'
Accounts payable and accrued liabilities	2,263,947	1,797,439
Current portion of finance lease obligation	43,311	'
Deferred stock-based compensation payable	287,664	1,911,775
Mortgage loan payable	1,513,284	1,575,000
Promissory notes to related parties	603,138	507,694
Derivative liabilities related to convertible promissory notes	366,590	135,263
Convertible promissory notes, net of unamortized discount	125,018	77,363
Unearned revenue	19,124	19,124
10% Convertible note	10,000	10,000
Total Current Liabilities	5,232,076	6,033,658
Non-current portion of finance lease obligation	81,452	'
License deposits	322,200	341,400
Total Liabilities	5,635,728	6,375,058
Commitments and Contingencies	'	'
Stockholders' Deficiency	'	'
Preferred Stock, $0.001 par value, 100,000,000 shares authorized, 141,473 and 72,883 shares issued and outstanding at December 31, 2013 and 2012, respectively	141	73
Common Stock, $0.0001 par value, 1,000,000,000 shares authorized, 327,749,176 and 305,078,818 shares issued and outstanding at December 31, 2013 and 2012, respectively	32,775	30,508
Additional paid-in capital	30,712,778	27,259,253
Accumulated deficit	-33,977,311	-31,227,121
Total Stockholders' Deficiency	-3,231,617	-3,937,287
Total Liabilities and Stockholders' Deficiency	$2,404,111	$2,437,771

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Balance Sheets [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized shares	100,000,000	100,000,000
Preferred stock, issued shares	141,473	72,883
Preferred stock, outstanding shares	141,473	72,883
Common stock, par value	$0.00	$0.00
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common stock, issued shares	327,749,176	305,078,818
Common stock, outstanding shares	327,749,176	305,078,818

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Statements of Operations [Abstract]	'	'
Sublicensing fee revenue	$19,200	$19,200
Total Revenues	19,200	19,200
Expenses:	'	'
Research and development costs	261,161	825,504
General and administrative expenses	1,660,812	3,332,205
Depreciation and amortization	66,485	65,509
Total Expenses	1,988,458	4,223,218
Loss from Operations	-1,969,258	-4,204,018
Other Income (Expense):	'	'
Decrease (Increase) in estimated fair value of embedded derivative liabilities	-210,390	130,146
Other income	'	60,000
Total other income (expense)	-210,390	190,146
Interest expense	-570,542	-516,211
Loss Before Income Taxes	-2,750,190	-4,530,083
Provision for income taxes	'	'
Net Loss	($2,750,190)	($4,530,083)
Basic net loss per share	($0.01)	($0.01)
Basic weighted average shares outstanding	334,010,734	302,946,983
Diluted net loss per share	($0.01)	($0.01)
Diluted weighted average shares outstanding	334,010,734	302,946,983

Statement_of_Stockholders_Equi

Statement of Stockholder's Equity/ Deficiency (USD $)	Total	Series A Preferred Stock, $0.001 par value per share	Common Stock, $0.0001 par value per share	Additional Paid-In Capital	Accumulated Deficit
Beginning Balance, Amount at Dec. 31, 2011	($1,751,291)	$73	$28,413	$24,917,261	($26,697,038)
Beginning Balance, Shares at Dec. 31, 2011	'	72,883	284,127,846	'	'
Issuance of common stock under equity line of credit with Dutchess Opportunity Fund II, LP, Shares	'	'	2,256,677	'	'
Issuance of common stock under equity line of credit with Dutchess Opportunity Fund II, LP amount	258,722	'	226	258,496	'
Issuance of common stock to director, Shares	'	'	551,281	'	'
Issuance of common stock to director, Amount	35,000	'	55	34,945	'
Issuance of common stock and warrants to son of a director, Share	'	'	5,747,560	'	'
Issuance of common stock and warrants to son of a director, Amount	379,724	'	575	379,149	'
Conversion of convertible promissory notes to common stock, Share	'	'	8,415,515	'	'
Conversion of convertible promissory notes to common stock, Amount	372,190	'	842	371,348	'
Issuance of common stock in satisfaction of promissory notes to related parties, Share	'	'	3,547,279	'	'
Issuance of common stock in satisfaction of promissory notes to related parties, Amount	231,767	'	354	231,413	'
Issuance of Anti-dilution shares of Common Stock to George J. Coates, Shares	'	'	18,593,313	'	'
Issuance of Anti-dilution shares of Common Stock to George J. Coates, Amount	1,611,768	'	1,859	1,609,909	'
Common stock awarded to officers and directors, Share	'	'	1,960,000	'	'
Common stock awarded to officers and directors, Amount	301,200	'	196	301,004	'
Cancelation of Anti-dilution shares of Common Stock to George J. Coates, Shares	'	'	-20,120,653	'	'
Cancelation of Anti-dilution shares of Common Stock to George J. Coates, Amount	-1,753,008	'	-2,012	-1,750,996	'
Stock compensation expense	713,932	'	'	713,932	'
Beneficial Conversion Feature on convertible promissory notes	192,792	'	'	192,792	'
Net loss for the Year	-4,530,083	'	'	'	-4,530,083
Ending Balance, Amount at Dec. 31, 2012	-3,937,287	73	30,508	27,259,253	-31,227,121
Ending Balance, Shares at Dec. 31, 2012	'	72,883	305,078,818	'	'
Issuance of common stock under equity line of credit with Dutchess Opportunity Fund II, LP, Shares	'	'	3,618,676	'	'
Issuance of common stock under equity line of credit with Dutchess Opportunity Fund II, LP amount	155,505	'	361	155,144	'
Issuance of common stock and warrants to son of a director, Share	'	'	4,666,666	'	'
Issuance of common stock and warrants to son of a director, Amount	125,000	'	467	124,533	'
Issuance of Anti-dilution shares of Common Stock to George J. Coates, Shares	'	'	35,037,131	'	'
Issuance of Anti-dilution shares of Common Stock to George J. Coates, Amount	2,181,483	'	3,504	2,177,979	'
Cancelation of Anti-dilution shares of Common Stock to George J. Coates, Shares	'	'	-35,037,131	'	'
Cancelation of Anti-dilution shares of Common Stock to George J. Coates, Amount	'	'	-3,504	3,504	'
Stock compensation expense	248,918	'	'	248,918	'
Beneficial Conversion Feature on convertible promissory notes	293,536	'	'	293,536	'
Issuance of Anti-dilution shares of Series A Preferred stock to George J. Coates, Shares	'	68,590	'	'	'
Issuance of Anti-dilution shares of Series A Preferred stock to George J. Coates	170,362	68	'	170,294	'
Conversion of 12% Convertible Promissory Notes, Shares	'	'	2,750,000	'	'
Conversion of 12% Convertible Promissory Notes	67,056	'	275	66,781	'
Conversion of 8% Convertible Promissory Notes, Shares	'	'	10,968,349	'	'
Conversion of 8% Convertible Promissory Notes	204,000	'	1,097	202,903	'
Exercise of Stock Purchase Warrants, Shares	'	'	666,667	'	'
Exercise of Stock Purchase Warrants	10,000	'	67	9,933	'
Net loss for the Year	-2,750,190	'	'	'	-2,750,190
Ending Balance, Amount at Dec. 31, 2013	($3,231,617)	$141	$32,775	$30,712,778	($33,977,311)
Ending Balance, Shares at Dec. 31, 2013	'	141,473	327,749,176	'	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Net Cash Flows Used in Operating Activities	'	'
Net loss for the Year	($2,750,190)	($4,530,083)
Adjustments to Reconcile Net Income (Loss) to Net Cash Used in Operating Activities:	'	'
Stock-based compensation expense	628,990	2,388,307
Accrued interest not paid	433,284	410,144
Deferred compensation expense	137,064	'
Increase (decrease) in fair value of embedded derivative liabilities	210,390	-130,146
Depreciation and amortization	66,485	65,509
Amortization of financing costs	10,246	11,822
Non-cash licensing revenues	-19,200	-19,200
Provision for slow moving and obsolete inventory	'	235,942
Recognition of unearned revenues	'	-10,000
Changes in Operating Assets and Liabilities:	'	'
Accounts receivable	'	-10
Deferred offering costs and other assets	-6,463	'
Deferred financing costs	4,283	'
Accounts payable and accrued liabilities	466,299	469,586
Net Cash (Used in) Operating Activities	-818,812	-1,108,129
Net Cash Provided by (Used in) Investing Activities	'	'
Cash Flows Provided by (Used in) Financing Activities:	'	'
Issuance of common stock under equity line of credit	155,506	258,722
Proceeds from sale/leaseback of equipment	132,550	'
Issuance of common stock and warrants to the son of a director	125,000	355,000
Issuance of convertible promissory notes	398,000	244,500
Issuance of promissory notes to related parties	172,093	270,755
Repayment of promissory notes to related parties	-76,650	-40,500
Repayment of mortgage Loan	-61,716	-55,000
Proceeds from exercise of stock warrants	10,000	'
Issuance of common stock to director	'	35,000
Net Cash Provided by Financing Activities	854,783	1,068,477
Net Increase (Decrease) in Cash	35,971	-39,652
Cash, beginning of period	13,303	52,955
Cash, end of period	49,274	13,303
Supplemental Disclosure of Cash Flow Information:	'	'
Cash paid during the period for interest	138,977	112,029
Supplemental Disclosure of Non-cash Financing Activities:	'	'
Issuance of common stock for anti-dilution, net of cancelled anti-dilution common shares	2,181,483	'
Conversion of convertible promissory notes	271,056	372,190
Conversion of promissory notes to related parties	'	231,768
TOTAL	$2,452,539	$603,958

The_Company_and_Summary_of_Sig

The Company and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
The Company and Summary of Significant Accounting Policies [Abstract]	'
THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	1. THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Nature of Organization
	Coates International, Ltd. is a Delaware corporation organized in October 1991 as successor-in-interest to a Delaware corporation of the same name incorporated in August 1988.  Coates International, Ltd. operates in Wall Township, New Jersey.
	The Company has acquired the exclusive licensing rights for the Coates spherical rotary valve (“CSRV®”) system technology in North America, Central America and South America (the “CSRV® License”). The CSRV® system technology has been developed over a period of more than 20 years by the Company’s founder George J. Coates and his son Gregory Coates. The CSRV® system technology is adaptable for use in piston-driven internal combustion engines of many types and has been patented in the United States and numerous countries throughout the world.
		The CSRV® system technology is designed to replace the intake and exhaust conventional “poppet valves” currently used in almost all piston-driven, automotive, truck, motorcycle, marine and electric power generator engines, among others. Unlike conventional valves which protrude into the engine cylinder, the CSRV® system technology utilizes spherical valves that rotate in a cavity formed between a two-piece cylinder head. The CSRV® system technology utilizes significantly fewer moving parts than conventional poppet valve assemblies. As a result of these design improvements, management believes that engines incorporating the CSRV® system technology (“Coates Engines”) will last significantly longer and will require less lubrication over the life of the engine, as compared to conventional engines. In addition, CSRV® Engines can be designed with larger openings into the engine cylinder than with conventional valves so that more fuel and air can be inducted into, and expelled from, the cylinder in a shorter period of time.  Larger valve openings permit higher revolutions-per-minute (RPM’s) and permit higher compression ratios with lower combustion chamber temperatures, allowing the Coates Engine to produce more power than equivalent conventional engines. The extent, to which higher RPM’s, greater volumetric efficiency and thermal efficiency can be achieved with the CSRV® system technology, is a function of the engine design and application.
	Hydrogen Reactor Technology Owned by George J. Coates
		George J. Coates has developed a hydrogen reactor, which rearranges H2O water molecules into HOH molecules also known as Hydroxy-Gas. The Hydroxy-Gas produced by the hydrogen reactor is then harvested for use as a type of fuel. Mr. Coates is continuing with development of this technology to enable the harvested Hydroxy-Gas to be utilized as the fuel source to power our patented CSRV® engines. Mr. Coates is continuing with research and development of the next application of this technology in an attempt to power larger, industrial engines. If successful, this application will only require a ready supply of water and would be suitable for stationary engines and generators. Conventional internal combustion engines employing poppet valve assemblies require lubrication and would experience excessive heat and friction if powered with Hydroxy-Gas. This, in turn, would cause the engines to burn out in a rather short period of time. The materials and components of the CSRV® engines do not require such lubrication and are designed to operate relatively trouble-free on Hydroxy-Gas as the engine fuel. There can be no assurance that this technology can be developed successfully, or that if developed, it will be feasible to penetrate the internal combustion engine market with this technology. Applications for patent protection of this technology will be filed upon completion of the research and development. At this time, no arrangements have been made between the Company and George J. Coates, owner of the technology, regarding licensing of the hydrogen reactor. Accordingly, the Company does not have any rights to manufacture, use, sell and distribute the Hydrogen Reactor technology, should it become commercially feasible to manufacture and distribute products powered by the Hydroxy-Gas fuel. The Company has been and continues to be responsible for all costs incurred related to the development of this technology.
	Basis of Presentation
		The accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and rules and regulations of the Securities and Exchange Commission (the “SEC”).
		Since the Company’s inception, the Company has been responsible for the development costs of the CSRV® technology in order to optimize the value of the licensing rights and has incurred related operational costs, the bulk of which have been funded primarily through cash generated from sales of stock, short term convertible promissory notes, capital contributions, loans made by George J. Coates, Bernadette Coates, his spouse and certain directors, fees received from research and development of prototype models, licensing fees and a small number of CSRV® engine generator sales. The Company has incurred substantial cumulative losses from operations since its inception. Losses from operations are expected to continue until the Coates Engines are successfully introduced into and accepted in the marketplace, or the Company receives substantial licensing revenues. These losses from operations were substantially related to research and development of the Company’s intellectual property rights, patent filing and maintenance costs and general and administrative expenses.
	As shown in the accompanying financial statements, the Company has incurred recurring losses from operations and, as of December 31, 2013, had a stockholders’ deficiency of ($3,232,000). The Company will be required to renegotiate the terms of an extension of a $1,513,000 mortgage loan which matures in July 2014, or successfully refinance the property with another mortgage lender, if possible. Failure to do so could adversely affect the Company’s financial position and results of operations. In addition, the current economic environment, which is characterized by tight credit markets, investor uncertainty about how to safely invest their funds and low investor confidence, has introduced additional risk and difficulty to the Company’s challenge to secure needed additional working capital. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management has instituted a cost control program intended to restrict variable costs to only those expenses that are necessary to complete its activities related to entering the production phase of operations, develop additional commercially feasible applications of the CSRV® system technology, seek additional sources of working capital and cover general and administrative costs in support of such activities. The Company has been actively undertaking efforts to secure new sources of working capital. At the December 31, 2013, the Company had negative working capital of ($5,059,000) compared with negative working capital of ($5,893,000) at the end of 2012.
	During the years ended December 31, 2013 and 2012, the Company raised $917,000 and $1,123,000, respectively, of new working capital from the following:
	Description		2013		2012
	Issuance of convertible promissory notes		$	398,000	$	244,000
	Sales of common stock under equity line of credit			156,000		259,000
	Proceeds from sale/leaseback of equipment			133,000		-
	Sales of shares of common stock and warrants to the son of a director			125,000		355,000
	Issuance of promissory notes to related parties, net of repayments			95,000		230,000
	Proceeds from exercise of common stock warrants			10,000		-
	Sales of common stock to a director			-		35,000
			$	917,000	$	1,123,000
	In the fourth quarter of 2011, the Company identified cracks on the lower engine heads of its Gen Sets that resulted from a defect in the manufacturing by one of its suppliers. Based on testing of the Gen Set to confirm the Company’s resolution of this problem, management believes it has determined the cause of this cracked head condition. The Company has been endeavoring to raise sufficient working capital, in order to procure new cast-steel head castings to resolve the cracked head problems with the engines originally shipped to Almont. Thereafter, we will undertake field testing of the Gen Sets, after which, we will begin to ramp-up production.
	The Company continues to actively seek out new sources of working capital; however, there can be no assurance that it will be successful in these efforts. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
	Certain amounts included in the accompanying financials statements for the year ended December 31, 2012 have been reclassified in order to make them comparable to the amounts presented for the year ended December 31, 2013.
	Majority-Owned Subsidiary
	CIL is currently the majority shareholder of Coates Hi-Tech Engines, Ltd. (“Coates Hi-Tech”), a Delaware corporation which was formed in July 2012. It has not commenced operations and has no assets. Accordingly, this subsidiary has not been consolidated with the accounts of CIL.
	For the year ended December 31, 2012, the financial statements of CIL were previously consolidated with the accounts of Coates Oklahoma Engine Manufacturing, Ltd. (“Coates Oklahoma”). In May 2013, Coates Oklahoma was shuttered and has since been formally dissolved. There were no outstanding obligations or expenses in dissolving this company. Accordingly, the financial statements for the year ended December 31, 2012 have been revised to present Coates International, Ltd. on an unconsolidated basis. There are no significant differences in the reported financial position or results of operations reported in the revised financial statements.
	Revenue Recognition
	Sales and cost of sales are recognized at the time of shipment, provided the risk of loss has transferred to the customer and collection of the sales price is reasonably assured. Shipping arrangements and costs are the responsibility of the customer.
	Revenue from research and development activities is recognized when collection of the related revenues is reasonably assured and, when applicable, in accordance with Accounting Standards Update No. 2010-17, “Milestone Method of Revenue Recognition, a consensus of the FASB Emerging Issues Task Force”. This standard provides guidance on defining a milestone and permits recognition of revenue from research and development that is contingent upon achievement of one or more specified milestones defined in the research and development arrangements which meet specified criteria for such revenue recognition.
	Unearned revenue represents a deposit from a customer for a CSRV® Gen Set order. Revenue is recognized as described above.
	License deposits, which are non-refundable, were received from the granting of sub-licenses and are recognized as earned, generally commencing upon the completion of certain tests  of the CSRV® products and acceptance by the licensee.  At that time, license revenue will be recognized ratably over the period of time that the sub-license has been granted using the straight-line method.  Upon termination of a sub-license agreement, non-refundable license deposits, less any costs related to the termination of the sub-license agreement, are recognized as revenue. Revenue from research and development activities is recognized when earned and realization is reasonably assured, provided that financial risk has been transferred from the Company to its customer.
	The Company commenced shipping production units to Almont under the Canadian Sublicense in April 2011 and began recognizing the license deposit of $300,000 on the Canadian Licensee as revenue on a straight-line basis over the approximate remaining life through 2027 of the last CSRV® technology patent in force, at that date.
	Research and Development
	Research and development costs are expensed when incurred. For the year ended December 31, 2012, the Company charged $115,000 to expense for the estimated remediation costs of previously sold Gen Sets, that were determined to have cracked heads.
	Intellectual Property
	Under a licensing agreement with George J. Coates and Gregory Coates, the Company obtained the rights to manufacture, use and sell the CSRV® engine technology throughout the territory defined as the Western Hemisphere. In accordance with GAAP, the Company is not permitted to record a value for this intellectual property because it was obtained from principal stockholders, and, accordingly this intangible asset is not reflected in the accompanying financial statements.
	Licensing Costs
	Under the CSRV® Licensing Agreement for the CSRV® engine technology, the Company is responsible for all costs in connection with applying for, obtaining and maintenance of patents to protect the CSRV® system technology. Such costs are expensed as incurred.
	Advertising Costs
	Advertising costs, which are included in general and administrative expenses, are expensed when incurred.  Advertising expense amounted to $3,000 and $5,000 for the years ended December 31, 2013 and 2012, respectively.
	Stock-Based Compensation
	Compensation expense relating to stock-based payments is recognized as an expense using the fair value measurement method. Under the fair value method, the estimated fair value of awards to employees is charged to income on a straight-line basis over the requisite service period, which is the earlier of the employee’s retirement eligibility date or the vesting period of the award. The Company incurs non-cash, stock-based compensation expense for stock options awarded and for awards of restricted shares of its common stock under it 2006 Stock Option and Incentive Plan.
	Deferred Compensation
	Deferred compensation represents salaries of George J. Coates and Bernadette Coates earned in 2013, but not paid in order to preserve the Company’s working capital. The Company intends to repay these amounts at such time that it has sufficient working capital and after the related party notes to George J. Coates and Bernadette Coates have been repaid with interest thereon.
	Inventory
	Inventory consists of raw materials and work-in-process, including overhead and is stated at the lower of cost or market determined by the first-in, first-out method. Inventory items designated as obsolete or slow moving are reduced to net realizable value. Market value is determined using current replacement cost.
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost.  Depreciation is computed using the straight-line method over the estimated useful life of the assets: 40 years for buildings and building improvements, 3 to 7 years for machinery and equipment and 5 to 10 years for furniture and fixtures.  Repairs and maintenance expenditures, which do not extend the useful lives of the related assets, are expensed as incurred.
	In the event that facts and circumstances indicate that long-lived assets may be impaired, an evaluation of recoverability is performed. Should such evaluation indicate that there has been an impairment of one or more long-lived assets, the cost basis of such assets would be adjusted accordingly, at that time.
	Income Taxes
	Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized and are adjusted when conditions indicate that deferred assets will be realized. Income tax expense (benefit) is the tax payable or refundable for the period, plus or minus the change during the period in deferred tax assets and liabilities.
	The Company evaluates any uncertain tax positions for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes. In the event recognition of an uncertain tax position is indicated, the Company measures the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. This process of evaluating and estimating uncertain tax positions and tax benefits requires the consideration of many factors, which may require periodic adjustments and which may not accurately forecast actual outcomes. Interest and penalties, if any, related to tax contingencies would be included in income tax expense.
	Loss per Share
	Basic net loss per share is based on the weighted average number of common shares outstanding without consideration of potentially dilutive shares of common stock. There were no shares of preferred stock outstanding with rights to share in the Company’s net income during the years ended December 31, 2013 and 2012. Diluted net income per share is based on the weighted average number of common and potentially dilutive common shares outstanding, when applicable.
	Use of Estimates
	The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These significant estimates include determining the fair value of convertible promissory notes containing embedded derivatives and variable conversion rates, determining a value for Series A Preferred Stock issued and certain limited anti-dilution rights granted to George J. Coates as more fully described in Note 15, assigning useful lives to the Company’s property, plant and equipment, determining an appropriate amount to reserve for obsolete and slow moving inventory, estimating a valuation allowance for deferred tax assets, assigning expected lives to, and estimating the rate of forfeitures of, stock options granted and selecting a trading price volatility factor for the Company’s common stock in order to estimate the fair value of the Company’s stock options on the date of grant or other appropriate measurement date. Actual results could differ from those estimates.

Concentrations_of_Credit_and_B

Concentrations of Credit and Business Risk	12 Months Ended
	Dec. 31, 2013
Concentrations of Credit and Business Risk [Abstract]	'
CONCENTRATIONS OF CREDIT AND BUSINESS RISK	'
	2. CONCENTRATIONS OF CREDIT AND BUSINESS RISK
	The Company maintains cash balances with one financial institution. Accounts at this institution are currently fully insured by the Federal Deposit Insurance Corporation.
	The Company’s operations are devoted to the development, application and marketing of the CSRV® system technology which was invented by George J. Coates, the Company’s founder, Chairman, Chief Executive Officer, President and controlling stockholder. Development efforts have been conducted continuously during this time. From July 1982 through May 1993, seven U.S. patents as well as a number of foreign patents were issued with respect to the CSRV® system technology. Since inception of the Company in 1988, all aspects of the business have been completely dependent upon the activities of George J. Coates.  The loss of George J. Coates’ availability or service due to death, incapacity or otherwise would have a material adverse effect on the Company's business and operations. The Company does not presently have any key-man life insurance in force for Mr. Coates.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2013
Fair Value of Financial Instruments [Abstract]	'
FAIR VALUE OF FINANCIAL INSTRUMENTS	'
	3. FAIR VALUE OF FINANCIAL INSTRUMENTS
	Cash, Other Assets, Accounts Payable and Accrued Liabilities and Other Liabilities
	With the exception of convertible promissory notes, the carrying amount of these items approximates their fair value because of the short term maturity of these instruments. The convertible promissory notes are reported at their estimated fair value, determined as described in more detail in Note 14.
	Limitations
	Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly affect the estimates.

Licensing_Agreement_and_Deferr

Licensing Agreement and Deferred Licensing Costs	12 Months Ended
	Dec. 31, 2013
Licensing Agreement and Deferred Licensing Costs [Abstract]	'
LICENSING AGREEMENT AND DEFERRED LICENSING COSTS	'
	4. LICENSING AGREEMENT AND DEFERRED LICENSING COSTS
	The Company holds a manufacturing, use, lease and sale license from George J. Coates and Gregory Coates for the CSRV® system technology in the territory defined as the Western Hemisphere (the “License Agreement”). Under the License Agreement, George J. Coates and Gregory Coates granted to the Company an exclusive, perpetual, royalty-free, fully paid-up license to the intellectual property that specifically relates to an internal combustion engine that incorporates the CSRV® system technology (the “CSRV® Engine”) and that is currently owned or controlled by them (the “CSRV® Intellectual Property”), plus any CSRV® Intellectual Property that is developed by them during their employment with the Company. In the event of insolvency or bankruptcy of the Company, the licensed rights would terminate and ownership would revert back to George J. Coates and Gregory Coates.
	Under the License Agreement, George J. Coates and Gregory Coates agreed that they will not grant any licenses to any other party with respect to the CSRV® Intellectual Property.
	At December 31, 2013 and 2012 deferred licensing costs, comprised of expenditures for patent costs incurred pursuant to the CSRV® licensing agreement, net of accumulated amortization, amounted to $51,000 and $55,000, respectively. Amortization expense for the years ended December 31, 2013 and 2012 amounted to $4,000 and $4,000, respectively.

Agreements_Assigned_to_Almont_

Agreements Assigned to Almont Energy, Inc.	12 Months Ended
	Dec. 31, 2013
Agreements Assigned to Almont Energy Inc [Abstract]	'
AGREEMENTS ASSIGNED TO ALMONT ENERGY, INC.	'
	5. AGREEMENTS ASSIGNED TO ALMONT ENERGY, INC.
	In 1999, the Company granted a sublicense to Well to Wire Energy, Inc. ("WWE"), an oil and gas company in Canada.  This sublicense provides for a $5,000,000 license fee to be paid to the Company and covers the use of the CSRV® system technology in the territory of Canada in the oil and gas industry (the “Canadian License”). A separate research and development agreement (“R&D Agreement”) provided for WWE to pay an additional $5,000,000 fee to the Company in consideration for the development and delivery of certain prototype engines. The Company completed development of the prototypes in accordance with this agreement at the end of 2007. The research and development agreement had not been reduced to the form of a signed, written agreement.
	In 2008, the Company also entered into an escrow agreement with WWE that provides conditional rights to a second sublicense agreement between the Company and WWE for the territory of the United States (the “US License”). The US License was deposited into an escrow account and the grant of the license will not become effective until the conditions for release from escrow are satisfied. The US License provides for a license fee of $50 million.
	In early 2010, with the prior consent of the Company, WWE assigned the Canadian License and the rights to the US License, subject to the terms and conditions of the Escrow Agreement, to Almont, a privately held, independent third party entity based in Alberta, Canada.
	The Escrow Agreement requires that Almont, as the assignee, make a payment (“Release Payment”) to the Company equal to the then remaining unpaid balance of the Canadian License licensing fee, the R&D Agreement fee and the down payment of $1,000,000 required under the US License. It is not likely that Almont will be able to make payments towards the Release Payment until the Company can raise sufficient new working capital to commence production and shipment of Gen Sets to Almont. At December 31, 2013, the remaining balance of the Release Payment was $5,847,000.
	In connection with the assignment of the Canadian License and the rights to the US License, Almont has also assumed all of the obligations set forth in the escrow agreement between the Company and WWE, with the following modifications:
	·	The Release Payment Date, as defined in the Escrow Agreement had been extended to March 19, 2012. In early 2012, we agreed to extend the Release Payment Date under the Escrow Agreement until March 2014 to compensate for the delay caused by the late delivery of Gen Sets. Provided that Almont remits this entire unpaid balance to the Company on or before the Release Payment Date, the US License will be released from escrow and granted to Almont. The Release Payment due date will be reset as appropriate once the Company commences its production phase of operations. Almont is required to remit to the Company 60% of all monies it raises from future equity or debt transactions, exclusive of proceeds from equipment purchase financing transactions, until the Release Payment is paid in full.
	·	Almont also became obligated to pay the $49 million balance of the US License Fee to the Company. Payment shall be made quarterly in an amount equal to 5% of Almont’s quarterly net profits. In addition, Almont is required to remit a portion of the proceeds it receives from equity or debt transactions, exclusive of equipment financing transactions to the Company until the entire balance of the US License fee is paid in full. However, the entire $49 million licensing fee is required to be paid on or before February 19, 2016.
	The Canadian License
	The Canadian License exclusively sublicenses within Canada the use of the CSRV® system technology for industrial engines designed to generate electrical power. Additional provisions of the Canadian License agreement are as follows:
	·	Sublicensee shall have the exclusive right to use, lease and sell electric power generators designed with the CSRV® system technology within Canada.
	·	Sublicensee will have a specified right of first refusal to market the electric power generators worldwide.
	·	Upon commencement of the production and distribution of the electric power generators, the minimum annual number of generators to be purchased by Sublicensee in order to maintain exclusivity is 120. The Company has temporarily waived this provision due to the delay in delivery of Gen Sets.  In the event Sublicensee fails to purchase the minimum 120 CSRV® generator engines during any year, Sublicensee will automatically lose its exclusivity. In such a case, Sublicensee would retain non-exclusive rights to continue to use and sell the CSRV® generator engines in the territory of Canada. Until otherwise agreed between the parties, the price per generator shall be $159,000.
	·	Sublicensee is required to pay a royalty to the Company equal to 5% of its annual modified gross profit (which has been defined as sales, less cost of sales, plus $400,000.
	·	All licensed rights under this license agreement related to the CSRV® system technology will remain with the Company.
	The US License
	The US License will, upon Almont satisfying the Release Payment, grant to Almont the right to use, sell and lease within the defined territory, Licensed Products manufactured by the Company which are designed to generate electrical power.  Licensed Products consist of CSRV® Valve Systems, CSRV® Valve Seals, CSRV® Rotary Valve Spheres, CSRV® Valve Components and CSRV® Engines. Almont is also obligated to pay a royalty to the Company equal to 2.5% of its annual modified gross profit (which has been defined as sales, less cost of sales, plus $400,000).
	The manufacture of any Licensed Products by Sublicensee is prohibited.  Sublicensee is required to procure all internal combustion engines incorporating the CSRV® Valve System from the Company or its designee. The license granted to Sublicensee is exclusive within the Territory, provided that Sublicensee satisfies the minimum annual purchase commitment of 120 internal combustion engines incorporating the CSRV® system technology, the Coates Engines and all component parts. The Company has temporarily waived this provision due to the delay in delivery of Gen Sets. The agreement also grants Sublicensee a right of first refusal in the event that the Company negotiates an offer with another third party for a worldwide license to use the Licensed Products for the generation of electrical power.
	The business plan of Almont, which is highly dependent on its ability to raise sufficient additional working capital, is based on its projected assessment of the marketplace demand for industrial generators and projects Gen Set purchases of up to 11,000 CSRV® Units per year over the next 5 years. The Company would not be able to accommodate that demand until it ramps up its production capacity, which would likely require several years, once it enters into large scale production. Almont intends to issue standard purchase orders, issued based on market and customer demand. The Company is unable to confirm any orders until it has sufficient working capital in place to manufacture generators on a larger scale. Almont plans to finance its purchases from cash flow and by way of project and/or equipment financing, proceeds from issuance of equity or corporate debt instruments and conventional bank financing.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2013
Inventory [Abstract]	'
INVENTORY	'
	6. INVENTORY
	Inventory at December 31, consisted of the following:
		2013			2012
	Raw materials	$	440,000		$	439,000
	Work-in-process		59,000			59,000
	Finished goods		-			-
	Less: Reserve for obsolescence		(387,000	)		(387,000	)
	Total	$	112,000		$	111,000
	During the year ended December 31, 2012, the Company determined that components and parts inventory with a carrying value of $236,000 became obsolete and, accordingly, charged this amount to research and development expense, thereby increasing the reserve for slow-moving and obsolete inventory to $387,000.

License_Deposits

License Deposits	12 Months Ended
	Dec. 31, 2013
License Deposits [Abstract]	'
LICENSE DEPOSITS	'
	7. LICENSE DEPOSITS
	License deposits, which are non-refundable, primarily relate to a $300,000 sublicense deposit received in prior years as a down payment on the Canadian License. The Company is recognizing the license deposit of $300,000 on the Canadian Licensee as revenue on a straight-line basis over the remaining life until 2027 of the last CSRV® technology patent in force, at that date. Sublicensing fee revenue for the years ended December 31, 2013 and 2012 amounted to $19,000 and $19,000, respectively.

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
PROPERTY, PLANT AND EQUIPMENT	'
	8. PROPERTY, PLANT AND EQUIPMENT
	Property, plant and equipment at cost, less accumulated depreciation, consists of the following at December 31:
		2013			2012
	Land	$	1,235,000		$	1,235,000
	Building		964,000			964,000
	Building improvements		83,000			83,000
	Machinery and equipment		658,000			658,000
	Furniture and fixtures		39,000			39,000
			2,979,000			2,979,000
	Less:  Accumulated depreciation		(799,000	)		(737,000	)
	Total	$	2,180,000		$	2,242,000
	Depreciation expense amounted to $62,000 and $61,000 for the years ended December 31, 2013 and 2012, respectively.

Mortgage_Loan_Payable

Mortgage Loan Payable	12 Months Ended
	Dec. 31, 2013
Mortgage Loan Payable [Abstract]	'
MORTGAGE LOAN PAYABLE	'
	9. MORTGAGE LOAN PAYABLE
	The Company has a mortgage loan on the land and building that serves as its headquarters and research and development facility which bears interest at the rate of 7.5% per annum and which matures in July 2014. Interest expense for the years ended December 31, 2013 and 2012 on this mortgage amounted to $114,000 and $122,000, respectively. The loan requires monthly payments of interest, plus $5,000 which is being applied to the principal balance. The remaining principal balance at December 31, 2013 was $1,513,000. The Company will be required to renegotiate the terms of a further extension of the mortgage loan or successfully refinance the property with another mortgage lender, if possible. Failure to do so, could adversely affect the Company’s financial position and results of operations.
	The loan is collateralized by a security interest in all of the Company’s assets, the pledge of five million shares of common stock of the Company owned by George J. Coates, which were deposited into escrow for the benefit of the lender and the personal guarantee of George J. Coates. The Company is not permitted to create or permit any secondary mortgage or similar liens on the property or improvements thereon without prior consent of the lender. Up to $500,000 of the principal balance of the mortgage loan may be prepaid each year without penalty. A prepayment penalty of 2% of the outstanding loan amount would be imposed if the loan is repaid in full at or before maturity unless such prepayment funds are obtained from a permanent mortgage loan with the lender.

Finance_Lease_Obligation

Finance Lease Obligation	12 Months Ended
	Dec. 31, 2013
Finance Lease Obligation [Abstract]	'
FINANCE LEASE OBLIGATION	'
	10. FINANCE LEASE OBLIGATION
	In August 2013, the Company entered into a sale/leaseback financing arrangement with Paradigm Commercial Capital Group Corp (“Paradigm”) pursuant to which it sold its research and development and manufacturing equipment in consideration for net cash proceeds of $133,000. These cash proceeds were net of a deposit on the lease of $15,000 and transaction costs of $5,000. Under this arrangement, The Company is leasing back the equipment over a 24-month period, with an option to extend the lease for an additional six months. The fixed recurring monthly lease payment amount is $8,000. If the Company does not exercise the six-month extension option, then the parties will negotiate a repurchase price to be paid by the Company for the equipment. If the Company does exercise its option to extend, then ownership of the equipment will automatically revert back to the Company at the end of the option period. The effective interest rate on this lease is 36.6%.
	In accordance with generally accepted accounting principles, this sale/leaseback is required to be accounted for as a financing lease. Under this accounting method, the equipment and accumulated depreciation remains on the Company’s books and records as if the Company still owned the equipment. This accounting treatment is in accordance with ASC 840-40-25-4, Accounting for Sale-Leaseback Transactions. In addition, the discounted present value of the lease payments is recorded as a lease finance obligation. The difference between the gross sales price for the equipment and the net proceeds received amounted to $20,000, which has been recorded as unamortized discount on finance lease obligation. This amount is being amortized to interest expense using the interest method over the 30-month term of the lease, including the option period. The finance lease obligation is secured by all of the equipment included in the sale/leaseback transaction.
	For the year ended December 31, 2013, the interest expense on this lease amounted to $21,000 which is included in interest expense in the accompanying statements of operations.

Accounts_Payable_and_Accrued_L

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2013
Account Payable and Accrued Liabilities [Abstract]	'
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	'
	11. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
	Accounts payable and accrued liabilities at December 31 are as follows:
		2013		2012
	Legal and professional fees	$	1,388,000	$	1,240,000
	General and administrative expenses		301,000		149,000
	Accrued interest expense		264,000		118,000
	Accrued compensation and benefits		196,000		175,000
	Research and development costs		115,000		115,000
	Total	$	2,264,000	$	1,797,000

Promissory_Notes_to_Related_Pa

Promissory Notes to Related Parties	12 Months Ended
	Dec. 31, 2013
Promissory Notes To Related Parties [Abstract]	'
PROMISSORY NOTES TO RELATED PARTIES	'
	12. PROMISSORY NOTES TO RELATED PARTIES
	During the years ended December 31, 2013 and 2012, the Company issued, in a series of transactions, promissory notes to George J. Coates and received cash proceeds of $105,000 and $195,000, respectively, and repaid promissory notes in the aggregate principal amount of $67,000 and $31,000, respectively. The promissory notes are payable on demand and provide for interest at the rate of 17% per annum, compounded monthly.
	During the years ended December 31, 2013 and 2012, the Company issued, in a series of transactions, promissory notes to Bernadette Coates, spouse of George J. Coates and received cash proceeds of $68,000 and $76,000, respectively, and repaid promissory notes in the aggregate principal amount of $10,000 and $10,000, respectively. The promissory notes were payable on demand and provided for interest at the rate of 17% per annum, compounded monthly.
	During the year ended December 31, 2012, the Company had outstanding promissory notes with two of its directors, Dr. Richard W. Evans and Dr. Frank J. Adipietro with principal balances of $120,000 and $50,000, respectively. In June 2012, by mutual agreement, the $120,000 principal amount promissory note issued to Dr. Evans and $10,000 principal amount of the promissory note issued to Dr. Adipietro was converted into 2,000,000 and 166,667 shares of common stock, respectively, at a conversion price of $0.06 per share. The $40,000 principal balance, plus accrued interest on the promissory note due to Dr. Adipietro was converted into 473,372 shares of common stock in October 2012. These notes were due on demand and provided for interest at the rate of 17% per annum, compounded monthly.
	For the year ended December 31, 2013 and 2012, aggregate interest expense on all promissory notes to related parties amounted to $130,000 and $78,000, respectively. Unpaid accrued interest on these promissory notes amounting to $230,000 is included in accounts payable and accrued liabilities in the accompanying balance sheet at December 31, 2013.

10_Convertible_Note_to_Related

10% Convertible Note to Related Party	12 Months Ended
	Dec. 31, 2013
10% Convertible Note to Related Party [Abstract]	'
10% CONVERTIBLE NOTE TO RELATED PARTY	'
	13. 10% CONVERTIBLE NOTE TO RELATED PARTY
	The 10% Convertible Note, which is held by Dr. Michael J. Suchar, a director, is convertible at the option of the holder, into shares of the Company’s common stock at an initial conversion rate that is determined by dividing the principal amount of the note being converted by $0.45. This convertible note is payable on demand. Interest shall accrue at the rate of 10% per annum and shall be payable at the time of repayment of principal. All interest shall be forfeited upon conversion, in which case the holder would be entitled to dividends declared, if any, on the Company’s common stock during the time the convertible note was outstanding. The Company has reserved 22,222 shares of its common stock for conversion of the remaining $10,000 balance of this note.

Convertible_Promissory_Notes_a

Convertible Promissory Notes and Embedded Derivative Liability	12 Months Ended
	Dec. 31, 2013
Convertible Promissory Notes and Embedded Derivative Liability [Abstract]	'
CONVERTIBLE PROMISSORY NOTES AND EMBEDDED DERIVATIVE LIABILITY	'
	14. CONVERTIBLE PROMISSORY NOTES AND EMBEDDED DERIVATIVE LIABILITY
	From time to time, the Company issues convertible promissory notes. The net proceeds from these transactions are used for general working capital purposes. The notes may be converted into shares of the Company’s common stock at a defined discount from the trading price of the common stock on the date of conversion. The conversion rate discount establishes a beneficial conversion feature (“BCF”) or unamortized discount which is required to be valued and accreted to interest expense over the six-month period until the conversion of the notes into restricted shares of common stock is permitted. In addition, the conversion formula meets the conditions that require accounting for them as derivative liability instruments.
	8% Convertible Promissory Notes
	At December 31, 2013, there were three 8% convertible promissory notes (“8% Notes”) in the principal amounts of $53,000, $47,000 and $33,000 which mature in May 2014, July 2014 and August 2014, respectively, if not converted prior thereto. The 8% Notes may be converted into unregistered shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at the Conversion Price, as defined below, in whole, or in part, at any time beginning 180 days after the date of issuance of the Notes, at the option of the holder. The Conversion Price shall be equal to 61% multiplied by the Variable Conversion Rate which is equal to the average of the three (3) lowest closing bid prices of the Common Stock during the ten (10) trading day period prior to the date of conversion. The 8% Notes also contain a prepayment option whereby the Company may, during the first 179 days the note is outstanding, prepay the 8% Note by paying 130% during the first 60 days, increasing in 5% increments each month to a maximum of 150% of the then outstanding unpaid principal, interest and any other amounts that might be due for penalties or any event of a default.
	In a series of transactions during 2013, 8% convertible promissory notes with an aggregate principal balance, including accrued interest of $204,000 were converted into 10,968,349 unregistered shares of common stock. In a series of transactions during 2012, $293,000 principal amount of convertible promissory notes, including accrued interest thereon were converted into 8,415,515 restricted shares of the Company’s common stock.
	The Company has reserved 46,750,000 shares of its unissued common stock for potential conversion of these 8% Notes.
	10% Convertible Promissory Notes
	The Company has also entered into two agreements with different investors, whereby, under each agreement, it is permitted to issue two $28,000 tranches of convertible promissory notes which bear interest at 10% per annum and mature on the one-year anniversary date of the funding (“10% Notes”). In December 2013, the Company issued a $28,000 convertible note under each agreement and received cash proceeds of $50,000. These notes mature in December 2014, if not converted prior thereto. The convertible notes provide for a 5% original issue discount on the principal amount of each tranche, which was netted against the amount funded to the Company. Each drawdown of the promissory note may be prepaid at any time within the first 90 days after funding. The holder may convert the 10% Notes into restricted shares of the Company’s common stock at any time beginning 180 days after the date of funding. The conversion rate shall be equal to 58% of the lowest daily volume weighted average price (“VWAP”) of the Company’s common stock over the 18 trading days ending on the date of conversion. The Company has reserved 7.8 million shares of its unissued common stock for potential conversion of these two 10% convertible notes.
	12% Convertible Promissory Notes
	The Company has also entered into an agreement whereby it is permitted to issue in a series of tranches up to $335,000 of convertible promissory notes which bear interest at 12% per annum and mature on the one-year anniversary date of the funding (“12% Notes”). In March 2013, the Company issued a $67,000, 12% Note under this arrangement and received cash proceeds of $60,000. In each of June, August and December 2013, the Company issued three additional $28,000, 12% Notes under this arrangement and received cash proceeds of $75,000. These notes mature in March 2014, June 2014, August 2014 and September 2014, respectively, if not converted prior thereto. The arrangement provides for an approximately 10.5% original issue discount on the principal amount of each tranche, which is netted against the amount funded to the Company. Each drawdown of the promissory note may be prepaid at any time within the first 90 days after funding, upon which the interest for the outstanding period will be forgiven. The holder may convert the 12% Notes into restricted shares of the Company’s common stock at any time beginning 180 days after the date of funding. The conversion rate shall be equal to the lesser of $0.035 per share or 60% of the lowest trade price of the Company’s common stock in the 25 trading days prior to the date of conversion. The Company has reserved 35 million shares of its unissued common stock for potential conversion of this 12% Note agreement.
	During the year ended December 31, 2013, 12% convertible promissory notes with a principal balance of $67,000, including accrued interest were converted into 2,750,000 unregistered shares of common stock.
	In accordance with GAAP, the estimated fair value of the embedded derivative liability related to the Convertible Notes is required to be remeasured at each balance sheet date. The estimated fair value of the embedded derivative liabilities related to promissory notes outstanding was measured as the aggregate estimated fair value, based on Level 2 inputs, which included the average of the quoted daily yield curve rates on six-month and one-year treasury securities and the calculated 12-month historical volatility rate on the Company’s common stock.
	The embedded derivative liability arises because, based on historical trading patterns of the Company’s stock, the formula for determining the Conversion Rate is expected to result in a different Conversion Rate than the closing price of the stock on the actual date of conversion (hereinafter referred to as the “Variable Conversion Rate Differential”. The estimated fair values of the derivative liabilities have been calculated based on a Black-Scholes option pricing model.
	The following table presents the details of the outstanding 8% Notes, 10% Notes and 12% Notes at December 31, 2013 and 2012, including the balance of the unamortized discount and the amount of the embedded derivative liability, where applicable:
		Principal Amount				Unamortized Discount		Embedded
								Derivative Liability
	Date Issued	December 31,	December 31,	Nominal	Effective	December 31,	December 31,	December 31,	December 31,
		2013	2012	Interest Rate	Interest Rate(1)	2013	2012	2013	2012
	12/11/13
	$28,000   N/A   10%  134% $22,000   N/A  $43,000   N/A
	12/10/13
	28,000   N/A   12%  117%  19,000   N/A   45,000   N/A
	12/9/13
	28,000   N/A   10%  134%  22,000   N/A   43,000   N/A
	11/27/13
	32,000   N/A   8%  133%  25,000   N/A   33,000   N/A
	10/11/13
	47,000   N/A   8%  147%  31,000   N/A   48,000   N/A
	8/14/13
	28,000   N/A   12%  147%  14,000   N/A   45,000   N/A
	8/8/13
	53,000   N/A   8%  147%  14,000   N/A   53,000   N/A
	6/4/13
	28,000   N/A   12%  92%  -   N/A   45,000   N/A
	3/21/13
	-   N/A   12%  76%  -   N/A   12,000   N/A
	11/23/12
	N/A  $33,000   8%  101%  N/A  $17,000   N/A  $41,000
	9/24/12
	N/A   32,000   8%  122%  N/A   14,000   N/A   41,000
	8/6/12
	N/A   43,000   8%  142%  N/A   12,000   N/A   53,000
	6/12/12
	N/A   12,000   8%  142%  N/A   -   N/A   -    $272,000  $120,000          $147,000  $43,000  $367,000  $135,000
	(1) The effective interest rate reflects the rate required to fully amortize the unamortized discount over the six-month period until the Notes become convertible.
	Other (expense) income resulting from the change in the estimated fair value of the embedded derivative liabilities amounted to ($210,000) and $130,000 for the years ended December 31, 2013 and 2012, respectively. These amounts are included in the accompanying statements of operations as (Increase) decrease in estimated fair value of embedded derivative liabilities. Interest expense resulting from accretion of the unamortized discount for the years ended December 31, 2013 and 2012 amounted to $283,000 and $295,000, respectively.
	The Company made the private placement of these securities in reliance upon Section 4(2) of the Securities Act of 1933, as amended (the “Act”), Rule 506 of Regulation D, and the rules and regulations promulgated thereunder, and/or upon any other exemption from the registration requirements of the Act, as applicable.

Capital_Stock

Capital Stock	12 Months Ended
	Dec. 31, 2013
Capital Stock [Abstract]	'
CAPITAL STOCK	'
	15. CAPITAL STOCK
	Common Stock
	The Company’s common stock is traded on OTCQB; the OTC market tier for companies that report to the SEC. Investors can find real-time quotes and market information for the Company at www.otcmarkets.com market system under the ticker symbol COTE. The Company is authorized to issue up to 1,000,000,000 shares of common stock, par value, $0.0001 per share (the “Common Stock”).
	Pursuant to anti-dilution provisions which became effective January 2012, Mr. Coates was awarded one share of restricted common stock for each new share of stock issued to any individual or entity that was not a member of, or controlled by, the Coates Family. On August 30, 2013, these anti-dilution provisions were canceled and Mr. Coates voluntarily returned all shares of common stock awarded to him under these provisions.
	The following common stock transactions occurred during the year ended December 31, 2013:
		·	In a series of transactions during 2013, the Company made private sales, pursuant to stock purchase agreements of 4,666,666 unregistered shares of its common stock and 5,566,668 common stock warrants to purchase one share of common stock at an exercise prices ranging from $0.015 to of $0.04 per share in consideration for $125,000 received from the son of Richard W. Evans, a director.
		·	In a series of transactions during 2013, the Company issued 3,618,676 registered shares of its common stock to Dutchess Opportunity Fund II, LP under an equity line of credit in consideration for $156,000.
		·	In a series of transactions in 2013, the Company issued 14,142,085 unregistered shares of its common stock to George J. Coates for anti-dilution protection related to new shares of common stock issued in 2013. The estimated value of these shares, based on the closing trading price of the stock on the dates of the issuances was $420,000. On August 30, 2013, these shares were voluntarily returned to the Company for cancellation, upon which the shares were restored to the authorized, but unissued status.
		·	In January 2013, the Company issued 20,895,046 unregistered shares of its common stock to George J. Coates in satisfaction of a deferred compensation liability consisting of 20,275,046 shares for anti-dilution protection for the year ended December 31, 2012 and a 620,000 share stock award originally granted in 2011. The value of these shares, based on the closing trading price on the dates of the anti-dilution or the date of the stock award was $1,761,000, of which $1,674,000 and $87,000 was charged to stock compensation expense during the years ended December 31, 2012 and 2011, respectively. On August 30, 2013, these shares were voluntarily returned to the Company for cancellation, upon which the shares were restored to the authorized, but unissued status.
		·	In connection with an agreement to issue up to $335,000 of convertible promissory notes, during 2013, the Company issued a $67,000 principal amount, 12% convertible promissory note and three $28,000 principal amount, 12% convertible promissory notes and received cash proceeds of $135,000, net of original issue discount of $16,000.
		·	The Company issued five 8% convertible promissory notes and received proceeds of $208,000, net of transaction costs.
		·	In a series of transactions during 2013, 8% convertible promissory notes with an aggregate principal balance of $204,000, including accrued interest were converted into 10,968,349 unregistered shares of common stock.
		·	A portion of a 12% convertible promissory note with a principal balance of $67,000, including accrued interest was converted into 2,750,000 unregistered shares of common stock.
		·	The Company received proceeds of $10,000 from the son of Richard W. Evans, a director for the exercise of stock purchase warrants with an exercise price of $0.015 per share and issued 666,667 unregistered shares of its common stock.
	The following common stock transactions occurred during the year ended December 31, 2012:
		·	The Company sold in a series of transactions, 5,557,375 restricted shares of its common stock, and 10,839,752 warrants to purchase one share of its common stock at exercise prices ranging from $0.045 to $0.12 per share and received proceeds of $355,000 from the son of Richard W. Evans, a director. These transactions were private sales of unregistered, restricted securities pursuant to stock purchase agreements.
		·	The Company issued 190,185 restricted shares of its common stock to the son of Richard W. Evans, a director in consideration for 185,185 tradable shares of common stock which were utilized to pay for services.
		·	The Company sold a total of 551,281 restricted shares of its common stock in consideration for $35,000 to Dr. Frank J. Adipietro, director. These transactions were private sales of unregistered, restricted securities pursuant to a stock purchase agreement.
		·	The Company sold a total of 2,256,677 registered shares of its common stock under an equity line of credit with Dutchess Opportunity Fund II, LP and received proceeds of $259,000. There were no offering costs related to the sales of these shares.
		·	In a series of transactions, $305,000 principal amount of convertible promissory notes, including accrued interest thereon was converted into 8,415,515 restricted shares of the Company’s common stock.
		·	The Company issued 1,100,000 and 240,000 restricted shares of its common stock to Dr. Richard W. Evans and Dr. Frank J. Adipietro, directors, respectively. These shares were originally awarded as compensatory stock awards in 2011.
		·	By mutual agreement, a $120,000 principal amount promissory note due to Dr. Richard W. Evans was converted into 2,000,000 restricted shares of the Company’s common stock.
		·	By mutual agreement, a $50,000 principal amount promissory note, plus accrued interest thereon of $7,000, due to Dr. Frank J. Adipietro, was converted into 639,939 restricted shares of the Company’s common stock.
		·	Under the anti-dilution arrangement which became effective January 1, 2012, George J. Coates was awarded 20,275,046 restricted shares of the Company’s common stock during the year ended December 31, 2012. Of this amount, 18,593,313 shares of common stock were initially issued throughout 2012. In December 2012, these shares were cancelled and restored to unissued status. The entire 20,275,046 shares of common stock awarded in 2012 were then reissued in January 2013. The estimated fair value of these shares was $1,674,000, which amount is included in stock-based compensation expense in the accompanying statement of operations for the year ended December 31, 2012.
	At December 31, 2013, the Company had reserved 121,424,724 shares of its common stock to cover the potential conversion of convertible securities and exercise of stock options and warrants.
	Preferred Stock and anti-dilution rights
	The Company is authorized to issue 100,000,000 new shares of preferred stock, par value, $0.001 per share (the “Preferred Stock”).  The Company may issue any class of the Preferred Stock in any series. The board shall have authority to establish and designate series, and to fix the number of shares included in each such series and the relative rights, preferences and limitations as between series, provided that, if the stated dividends and amounts payable on liquidation are not paid in full, the shares of all series of the same class shall share ratably in the payment of dividends including accumulations, if any, in accordance with the sums which would be payable on such shares if all dividends were declared and paid in full, and in any distribution of assets other than by way of dividends in accordance with the sums which would be payable on such distribution if all sums payable were discharged in full. Shares of each such series when issued shall be designated to distinguish the shares of each series from shares of all other series.
	During the year ended December 31, 2013, the board designated an additional 900,000 shares of preferred stock as Series A Preferred Stock bringing the total designation to 1,000,000 shares of Series A Preferred Stock, $0.001, par value per share. Each share of Series A Preferred Stock entitles the holder of record to the right to vote 10,000 shares of common stock with respect to all matters that are submitted to a vote of shareholders. The Series A Preferred Stock does not provide the holder any rights to share in dividends or any distribution of assets to any other shareholders of any other class of the Company’s securities in a liquidation or for any other purpose.
	In order to enable the Company to raise needed working capital, an anti-dilution arrangement was established which authorized the issuance of shares of Series A Preferred Stock to George J. Coates to restore the Coates Family’s voting percentage upon any future issuance of new shares of the Company’s common stock as a result of a sale or conversion of securities into common stock (except that no Series A Preferred Stock shall be issued to George J. Coates to restore the Coates Family voting percentage in connection with any new shares of common stock issued upon sale or conversion of the Company’s securities pursuant to public offerings by the Company).
	During the year ended December 31, 2013, 68,590 shares of Series A Preferred Stock were granted and issued to George J. Coates pursuant to this anti-dilution agreement resulting in the right to 685,900,000 aggregate additional votes. No shares of Series A Preferred Stock were granted or issued during the year ended December 31, 2012, because this anti-dilution arrangement was temporarily discontinued in 2012 and reinstated in 2013.
	Each issuance of shares of Series A Preferred Stock to George J. Coates did not have any effect on the share of dividends or liquidation value of the holders of the Company’s common stock. However, the voting rights of the holders of the Company’s common stock are diluted with each issuance.
	In 2010, the Company arranged for an independent professional services firm to determine the estimated fair value of the shares of Series A Preferred Stock provided to Mr. Coates. Based on this estimated valuation, the aggregate estimated fair value of the Series A Preferred Stock issued to Mr. Coates in 2013 amounted to $170,000. This amount, which did not require any outlay of cash, was recorded as stock-based compensation expense in the accompanying statement of operations for the year ended December 31, 2013.

Unearned_Revenue

Unearned Revenue	12 Months Ended
	Dec. 31, 2013
Unearned Revenue [Abstract]	'
UNEARNED REVENUE	'
	16. UNEARNED REVENUE
	The Company received a non-refundable deposit from Almont in connection with its orders for natural gas fueled electric power CSRV® engine generators. The unused balance these deposited funds of $19,000, is included in unearned revenue in the accompanying balance sheet at December 31, 2013 and 2012.

Sublicensing_Fee_Revenue

Sublicensing Fee Revenue	12 Months Ended
	Dec. 31, 2013
Sublicensing Fee Revenue [Abstract]	'
SUBLICENSING FEE REVENUE	'
	17. SUBLICENSING FEE REVENUE
	Sublicensing fee revenue for the year ended December 31, 2013 and 2012 amounted to $19,000 and $19,000, respectively. The Company commenced shipping production units to Almont under the Canadian Sublicense in April 2011 and began recognizing the license deposit of $300,000 on the Canadian Licensee as revenue on a straight-line basis over the approximate remaining life until 2027 of the last CSRV® technology patent in force at that date.

Other_Income

Other Income	12 Months Ended
	Dec. 31, 2013
Other Income [Abstract]	'
OTHER INCOME	'
	18. OTHER INCOME
	Other income includes insurance proceeds of $50,000 related to business interruption losses caused by the superstorm known as Sandy in November 2012. These proceeds reimbursed costs incurred included in operating expenses in the accompanying statement of operations for the year ended December 31, 2012. The balance of the other income of $10,000 is from the recognition of non-refundable unearned income related to the termination of merger discussions with a Chinese manufacturer.

Income_Loss_Per_Share

Income (Loss) Per Share	12 Months Ended
	Dec. 31, 2013
Income (Loss) Per Share [Abstract]	'
INCOME (LOSS) PER SHARE	'
	19. INCOME (LOSS) PER SHARE
	At December 31, 2013, the Company had 45,970,314 shares of common stock potentially issuable upon assumed conversion of:
	Description		Number of		Exercise			Number		Number
			Underlying		Price			Vested		Non-Vested
			Shares of
			Common
			Stock
	Common stock options			100,000	$	0.042			-		100,000
	Common stock options			5,607,000		0.06			5,607,000		-
	Common stock options			1,800,000		0.24			1,800,000		-
	Common stock options			2,000,000		0.25			2,000,000		-
	Common stock options			50,000		0.39			50,000		-
	Common stock options			360,000		0.4			360,000		-
	Common stock options			100,000		0.43			100,000		-
	Common stock options			1,750,000		0.44			1,750,000		-
	Common stock options			30,000		1			30,000		-
	Common stock warrants			500,000		0.02			N/A		N/A
	Common stock warrants			666,667		0.0225			N/A		N/A
	Common stock warrants			1,000,000		0.025			N/A		N/A
	Common stock warrants			333,333		0.03			N/A		N/A
	Common stock warrants			2,000,001		0.035			N/A		N/A
	Common stock warrants			500,000		0.04			N/A		N/A
	Common stock warrants			333,333		0.045			N/A		N/A
	Common stock warrants			400,000		0.05			N/A		N/A
	Common stock warrants			2,181,819		0.055			N/A		N/A
	Common stock warrants			2,000,000		0.06			N/A		N/A
	Common stock warrants			4,269,838		0.0625			N/A		N/A
	Common stock warrants			571,429		0.07			N/A		N/A
	Common stock warrants			666,666		0.09			N/A		N/A
	Common stock warrants			416,667		0.12			N/A		N/A
	Common stock warrants			1,200,000		0.25			N/A		N/A
	Common stock warrants			833,333		0.27			N/A		N/A
	Common stock warrants			333,333		0.3			N/A		N/A
	Common stock warrants			153,846		0.325			N/A		N/A
	Common stock warrants			1,028,570		0.35			N/A		N/A
	$10,000, 10% Convertible promissory note			22,222		0.45			N/A		N/A
	8% Convertible promissory notes			6,445,105		(1	)		N/A		N/A
	10% Convertible promissory notes			3,160,920		(1	)		N/A		N/A
	12% Convertible promissory notes			5,156,232		(1	)		N/A		N/A
	Total			45,970,314
		-1	The principal amount of convertible promissory notes outstanding at December 31, 2013, was $272,000. Under the convertible terms of these notes, the number of share of common stock into which these notes are convertible is variable because the conversion rates of the notes are based on the trading price of the common stock over a defined a number of trading days leading up to the conversion date during a defined conversion rate pricing period. The actual number of shares underlying these convertible instruments will likely vary from the number assumed above. The number of shares underlying these convertible notes was determined based on the defined conversion rates of the various convertible notes, assuming conversion had occurred as of December 31, 2013.
	At December 31, 2012, the Company had 36,658,270 shares of common stock potentially issuable upon assumed conversion of:
	Description		Number of		Exercise			Number		Number
			Underlying		Price			Vested		Non-Vested
			Shares of
			Common
			Stock
	Common stock options			5,607,000	$	0.06			-		5,607,000
	Common stock options			1,800,000		0.24			1,800,000		-
	Common stock options			2,000,000		0.25			2,000,000		-
	Common stock options			50,000		0.39			50,000		-
	Common stock options			360,000		0.4			360,000		-
	Common stock options			100,000		0.43			100,000		-
	Common stock options			1,750,000		0.44			1,750,000		-
	Common stock options			30,000		1			30,000		-
	Common stock warrants			333,333		0.045			N/A		N/A
	Common stock warrants			400,000		0.05			N/A		N/A
	Common stock warrants			2,181,819		0.055			N/A		N/A
	Common stock warrants			2,000,000		0.06			N/A		N/A
	Common stock warrants			4,269,838		0.0625			N/A		N/A
	Common stock warrants			571,429		0.07			N/A		N/A
	Common stock warrants			666,666		0.09			N/A		N/A
	Common stock warrants			416,667		0.12			N/A		N/A
Common stock warrants			1,200,000		0.25			N/A		N/A
Common stock warrants			833,333		0.27			N/A		N/A
Common stock warrants			333,333		0.3			N/A		N/A
Common stock warrants			153,846		0.325			N/A		N/A
Common stock warrants			1,028,570		0.35			N/A		N/A
$10,000, 10% Convertible promissory note			22,222		0.45			N/A		N/A
8% Convertible promissory notes			10,550,214		(1	)		N/A		N/A
Total			36,658,270
	-1	The principal amount of convertible promissory notes outstanding, none of which were eligible for conversion at December 31, 2012, was $120,000. The conversion rate is variable as it is equal to the average of the three lowest closing bid prices during the ten trading days prior to the date of conversion. The actual number of shares underlying these convertible instruments will likely vary from the number assumed above. The number of shares underlying these convertible notes was determined based on the three lowest closing bid prices during the ten trading days prior to December 31, 2012.
For the years ended December 31, 2013 and 2012, none of the potentially issuable shares of common stock were assumed to be converted because the Company incurred a net loss in those years and the effect of including them in the calculation would have been anti-dilutive.

Stock_Options

Stock Options	12 Months Ended
	Dec. 31, 2013
Stock Options [Abstract]	'
STOCK OPTIONS	'
	20. STOCK OPTIONS
	The Company’s 2006 Stock Option and Incentive Plan (the “Stock Plan”) was adopted by the Company’s board in October 2006. In September 2007, the Stock Plan, by consent of George J. Coates, majority shareholder, was adopted by our shareholders. The Stock Plan provides for the grant of stock-based awards to employees, officers and directors of, and consultants or advisors to, the Company and its subsidiaries, if any. Under the Stock Plan, the Company may grant options that are intended to qualify as incentive stock options (“incentive stock options”) within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), options not intended to qualify as incentive stock options (“non-statutory options”), restricted stock and other stock-based awards. Incentive stock options may be granted only to employees of the Company. A total of 12,500,000 shares of common stock may be issued upon the exercise of options or other awards granted under the Stock Plan.  The maximum number of shares with respect to which awards may be granted during any one year to any employee under the Stock Plan shall not exceed 25% of the 12,500,000 shares of common stock covered by the Stock Plan.
	The Stock Plan is administered by the board and the Compensation Committee.  Subject to the provisions of the Stock Plan, the board and the Compensation Committee each has the authority to select the persons to whom awards are granted and determine the terms of each award, including the number of shares of common stock subject to the award. Payment of the exercise price of an award may be made in cash, in a “cashless exercise” through a broker, or if the applicable stock option agreement permits, shares of common stock or by any other method approved by the board or Compensation Committee.  Unless otherwise permitted by the Company, awards are not assignable or transferable except by will or the laws of descent and distribution.
	Upon the consummation of an acquisition of the business of the Company, by merger or otherwise, the board shall, as to outstanding awards (on the same basis or on different bases as the board shall specify), make appropriate provision for the continuation of such awards by the Company or the assumption of such awards by the surviving or acquiring entity and by substituting on an equitable basis for the shares then subject to such awards either (a) the consideration payable with respect to the outstanding shares of common stock in connection with the acquisition, (b) shares of stock of the surviving or acquiring corporation, or (c) such other securities or other consideration as the board deems appropriate, the fair market value of which (as determined by the board in its sole discretion) shall not materially differ from the fair market value of the shares of common stock subject to such awards immediately preceding the acquisition. In addition to, or in lieu of the foregoing, with respect to outstanding stock options, the board may, on the same basis or on different bases as the board shall specify, upon written notice to the affected optionees, provide that one or more options then outstanding must be exercised, in whole or in part, within a specified number of days of the date of such notice, at the end of which period such options shall terminate, or provide that one or more options then outstanding, in whole or in part, shall be terminated in exchange for a cash payment equal to the excess of the fair market value (as determined by the board in its sole discretion) for the shares subject to such stock options over the exercise price thereof.  Unless otherwise determined by the board (on the same basis or on different bases as the board shall specify), any repurchase rights or other rights of the Company that relate to a stock option or other award shall continue to apply to consideration, including cash, that has been substituted, assumed or amended for a stock option or other award pursuant to these provisions. The Company may hold in escrow all or any portion of any such consideration in order to effectuate any continuing restrictions.
	The board may at any time provide that any stock options shall become immediately exercisable in full or in part, that any restricted stock awards shall be free of some or all restrictions, or that any other stock-based awards may become exercisable in full or in part or free of some or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be.
	The board or Compensation Committee may, in its sole discretion, amend, modify or terminate any award granted or made under the Stock Plan, so long as such amendment, modification or termination would not materially and adversely affect the participant.
	In December 2013, options to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.042 per share were granted to Barry C. Kaye. These options become vested in December 2014 and expire in December 2028.
	In June 2012, options to purchase 1,815,000, 3,125,000 and 667,000 shares of the Company’s common stock at an exercise price of $0.06 per share were granted to George J. Coates, Dr. Richard W. Evans and Dr. Frank J. Adipietro, respectively. These options became fully vested June 2013 and expire June 2027.
	The estimated fair value of stock options granted during the years ended December 31, 2013 and 2012 was $4,000 and $358,000, respectively. The estimated fair value of 5,607,000 and 3,800,000 stock options which vested during the years ended December 31, 2013 and 2012 was $358,000 and $917,000, respectively. The estimated fair value of 100,000 nonvested stock options at December 31, 2013 was $4,000. Total compensation cost related to nonvested stock options at December 31, 2013 that has not been recognized was $4,000. This non-cash compensation expense will be recognized in the future over a remaining weighted average period of approximately 11 months.
	For the years ended December 31, 2013 and 2012, the Company recorded non-cash stock-based compensation expense amounting to $179,000 and $714,000, respectively, relating to stock option grants. For the years ended December 31, 2013 and 2012, $15,000 and $229,000, respectively, of this amount was allocated to research and development expenses and $164,000 and $485,000, respectively, of this amount is included in general and administrative expenses in the accompanying statements of operations.
	A summary of the activity in the Company’s Stock Option Plan is as follows:
			Exercise				Number				Weighted		Number		Weighted		Weighted
			Price Per				Outstanding				Average		Exercisable		Average		Average
			Share								Remaining				Exercise		Fair Value
											Contractual Life				Price		Per Stock Option
																	at Date of
																	Grant
	Balance, 1/1/12			0.25 -1.00				6,090,000				12		2,290,000		0.32		0.28
	Stock options granted			0.06				5,607,000				15		-		0.06		0.06
	Vested			0.24				-				14		1,800,000		0.24		0.24
	Vested			0.25				-				14		2,000,000		0.25		0.24
	Balance, 12/31/12			0.600 -1.000				11,697,000				12		6,090,000		0.194		0.18
	Stock options granted			0.042				100,000				15		-		0.042		0.042
	Vested			0.24				-				14		5,607,000		0.24		0.24
	Balance, 12/31/13			0.042 – 1.000				11,797,000				12		11,697,000		0.193		0.179
	The weighted average fair value of the Company's stock options was estimated using the Black-Scholes option pricing model which requires highly subjective assumptions including the expected stock price volatility. These assumptions were as follows:
	●	Historical stock price volatility		139% - 325%
	●	Risk-free interest rate		0.21%-4.64%
	●	Expected life (in years)		4
	●	Dividend yield		0
	The valuation assumptions were determined as follows:
	●	Historical stock price volatility: The Company utilized the volatility in the trading of its common stock computed for the 12 months of trading immediately preceding the date of grant for options granted in 2013 and 2012.
	●	Risk-free interest rate: The Company bases the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time of the grant for a period that is commensurate with the assumed expected option life.
	●	Expected life: The expected life of the options represents the period of time options are expected to be outstanding. The Company has very limited historical data on which to base this estimate. Accordingly, the Company estimated the expected life based on its assumption that the executives will be subject to frequent black out periods during the time that the stock options will be exercisable and based on the Company’s expectation that it will complete its research and development phase and commence its initial production phase. The vesting period of these options was also considered in the determination of the expected life of each stock option grant.
	●	No expected dividends.
	The following table sets forth information with respect to stock options outstanding at December 31, 2013:
	Name		Title		Number of							Option
					Shares of				Exercise			Expiration
					Common Stock				Price per			Date
					Underlying				Share
					Stock Options
	George J. Coates		Chairman, Chief  Executive Officer and President			1,000,000	-1		$	0.44		10/23/21
						50,000	-1			0.43		11/4/24
						275,000	-1			0.4		11/17/25
						1,800,000	-1			0.25		7/25/26
						1,815,000	-1			0.06		6/24/27
	Gregory Coates		Director and President, Technology Division			500,000	-1			0.44		10/23/21
						1,800,000	-1			0.24		8/8/26
	Barry C. Kaye		Director, Treasurer and Chief Financial Officer			125,000	-1			0.44		10/18/21
						100,000	-2			0.042		12/11/28
	Dr. Frank J. Adipietro		Non-employee Director			25,000	-1			0.44		3/28/2022
						50,000	-1			0.43		11/3/24
						85,000	-1			0.4		11/17/25
						667,000	-1			0.06		6/24/27
	Dr. Richard W. Evans		Non-employee Director and Secretary			25,000	-1			0.44		3/28/2022
						50,000	-1			0.39		12/27/24
						200,000	-1			0.25		2/15/26
						3,125 000	-1			0.06		6/20/27
	Dr. Michael J. Suchar		Non-employee Director			25,000	-1			0.44		3/28/2022
	Richard Whitworth		Non-employee Director			25,000	-1			0.44		3/28/2022
	William Wolf. Esq.		Outside General Counsel			25,000	-1			0.44		4/4/2022
	Company Supplier		Company Supplier			30,000	-1			1		10/7/2015
		(1) These stock options are fully vested.
	(2) These options will fully vest in December 2014.

Investment_Agreement_with_Dutc

Investment Agreement with Dutchess Opportunity Fund II, L.P.	12 Months Ended
	Dec. 31, 2013
Investment Agreement with Dutchess Opportunity Fund II, L.P. [Abstract]	'
INVESTMENT AGREEMENT WITH DUTCHESS OPPORTUNITY FUND II, L.P.	'
	21. INVESTMENT AGREEMENT WITH DUTCHESS OPPORTUNITY FUND II, L.P.
	In June 2011, the Company entered into an investment agreement (the “Investment Agreement”) with Dutchess Opportunity Fund II, LP, a Delaware limited partnership (“Dutchess”). Pursuant to the terms of the Investment Agreement, Dutchess committed to purchase, in a series of purchase transactions (“Puts”) registered shares of the Company’s common stock over a period of up to thirty-six (36) months. In accordance with this agreement, 17,500,000 shares of the Company’s common stock were registered for resale Form S-1 with the SEC.
	The amount that the Company is entitled to request with each Put delivered to Dutchess is equal to, at its option, either (i) two hundred percent (200%) of the average daily volume (U.S. market only) of its common stock for the three (3) Trading Days prior to the applicable Put Notice Date, multiplied by the average of the three (3) daily closing prices immediately preceding the Put Date or (ii) (x) the lesser of the value of the unsold registered shares under the equity line of credit based on the closing price of the common stock on the day prior to the Put Notice, or (y) five hundred thousand dollars ($500,000). The purchase price to be paid by Dutchess for the shares of common stock covered by each Put will be equal to ninety-four percent (94%) of the lowest daily volume weighted average prices of the common stock during the period beginning on the Put Notice Date and ending on and including the date that is five (5) trading days after such Put Notice Date (the “Pricing Period”). “Put Notice Date” is the trading day immediately following the day on which Dutchess receives a Put Notice from the Company. During the years ended December 31, 2013 and 2012, the Company sold 3,618,676 and 2,256,677 shares of its common stock, respectively, under this equity line of credit and received proceeds of $156,000 and $259,000, respectively.
	In connection with the Investment Agreement, the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) with Dutchess. Pursuant to the Registration Rights Agreement, the Company filed a registration statement on Form S-1 with the Securities and Exchange Commission (“SEC”) which became effective in August 2011, covering 17,500,000 shares of the common stock underlying the Investment Agreement. The effectiveness of the registration statement temporarily lapsed in 2012 as it no longer contained current financial statements as required by SEC rules and regulations. In April 26, 2013, an amendment was filed with the SEC to provide the current financial statement information and the effectiveness of the registration statement was reinstated.
	As of December 31, 2013, there remained 11,614,647 unsold registered shares of common stock in connection with this equity line of credit arrangement.

Placement_Agency_Agreement_wit

Placement Agency Agreement with Stonegate Securities, Inc.	12 Months Ended
	Dec. 31, 2013
Placement Agency Agreement with Stonegate Securities, Inc. [Abstract]	'
PLACEMENT AGENCY AGREEMENT WITH STONEGATE SECURITIES, INC.	'
	22. PLACEMENT AGENCY AGREEMENT WITH STONEGATE SECURITIES, INC.
	The Company entered into a placement agent agreement with Stonegate Securities, Inc. (“Stonegate”) to act as its placement agent. Stonegate has the right during the Contract Period to identify for the Company prospective Purchasers in one or more Placements of Securities, the type and dollar amount being as mutually agreed to by the parties. The term of the agreement shall continue until cancelled by either party upon ten (10) days written notice.
	As compensation for services rendered by Stonegate in connection with the successful placements, the Company has agreed to pay Stonegate a fee of eight percent (8%) of the gross proceeds from the sale of Securities it places.  No fees shall be due and payable in connection with sales of Securities placed with investors not introduced to the Company by Stonegate or by a direct or indirect party previously introduced to the Company as a result of the efforts of Stonegate.
	Upon closing of a Placement, the Company is required to issue to Stonegate restricted shares of common stock of the Company in an amount equal to two percent (2%) of the total number of shares of common stock sold, and/or in the event of a sale of convertible securities, the number of shares of common stock that would be potentially received upon a conversion of any convertible securities sold in the Placement.  The number of such shares to be issued would be reduced by 200,000 shares of common stock originally issued to Stonegate upon execution of this agreement.
	The Company shall also reimburse Stonegate for reasonable, actual out-of-pocket expenses incurred by Stonegate, provided, however, that such amount in total shall not exceed one percent (1%) of the gross proceeds of securities placed pursuant to this placement agent agreement. At this time, there have been no private placement transactions undertaken with the assistance of Stonegate.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	23. INCOME TAXES
	Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company’s assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company’s tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases.
	Deferred tax assets increased by $834,000 and $1,470,000 for the years ended December 31, 2013 and 2012, respectively. These amounts were fully offset by a corresponding decrease in the tax valuation allowance resulting in no net change in deferred tax assets, respectively, during these periods.
	No liability for unrecognized tax benefits was required to be reported at December 31, 2013 and 2012.  Based on the Company's evaluation, it has concluded that there are no significant uncertain tax positions requiring recognition in the Company's financial statements.  The Company's evaluation was performed for tax years ended 2009 through 2012, the only periods subject to examination.  The Company believes that its income tax positions and deductions will be sustained on audit and does not anticipate that adjustments, if any, will result in a material change to its financial position. For the years ended December 31, 2013 and 2012, there were no penalties or interest related to the Company’s income tax returns.
	Total deferred tax assets and valuation allowances are as follows at December 31:
		2013			2012
	Current deferred tax asset - inventory reserve	$	195,000		$	195,000
	Non-Current Deferred Tax Assets:
	Net operating loss carryforwards		6,201,000			5,774,000
	Stock-based compensation expense		1,688,000			1,436,000
	Accrued liabilities not paid		481,000			492,000
	Deferred compensation not paid within 2.5 months		115,000			-
	Accrued interest on notes to related parties		115,000			64,000
	Total long-term deferred tax assets		8,600,000			7,766,000
	Total deferred tax assets		8,795,000			7,961,000
	Less: valuation allowance		(8,795,000	)		(7,961,000	)
	Net deferred tax assets	$	-		$	-
	The differences between income tax (benefit) provision in the financial statements and the income tax (benefit) provision computed at the U.S. Federal statutory rate of 34% at December 31 are as follows:
		2013			2012
	Federal tax provision (benefit) at the statutory rate		34	%		34	%
	State income tax provision (benefit), net of federal benefit		(2.7	)		(2.7	)
	Net change in net operating loss carryforwards		(15.5	)		(16.6	)
	Stock-based compensation expense		(9.1	)		(15.6	)
	Accrued interest not deductible for tax return purposes		(6.0	)		(1.2	)
	Deferred compensation not paid within 2.5 months		(4.2	)		-
	(Increase) Decrease in estimated fair value of embedded derivative liabilities		(3.1	)		2.9
	Provision for slow-moving and obsolete inventory		-			(2.1	)
	Accrued liabilities not deductible for tax return purposes		0.4			(1.1	)
	Officer’s life insurance		(0.2	)		-
	Total		(6.4	)		(2.4	)
	Valuation allowance		6.4			2.4
	Effective tax rate		0	%		0	%
	At December 31, 2013, the Company had available, $16,677,000 of net operating loss carryforwards which may be used to reduce future federal taxable income, expiring between 2018 and 2032. At December 31, 2013, the Company had available $7,835,000 of net operating loss carryforwards which may be used to reduce future state taxable income, expiring between 2014 and 2033.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	24. RELATED PARTY TRANSACTIONS
	Issuances of Common Stock and Warrants
	Issuances of common stock and common stock warrants to related parties during the years ended December 31, 2013 and 2012 to related parties are discussed in detail in Note 15.
	Issuances of common stock under anti-dilution arrangements to George J. Coates during the year ended December 31, 2012 are discussed in detail in Note 15.
	Conversions of promissory notes to related parties converted into restricted shares of the Company’s common stock are discussed in detail in Note 12.
	Issuances of Promissory Notes
	Issuances of promissory notes to related parties during the years ended December 31, 2013 and 2012 to related parties are discussed in detail in Note 12.
	The promissory notes to related parties are payable on demand and provide for interest at the rate of 17% per annum, compounded monthly.
	At December 31, 2013, interest accrued but not paid on outstanding promissory notes to related parties, aggregated $230,000.
	Stock Options Granted
	Stock options granted to related parties during the years ended December 31, 2013 and 2012 are discussed in detail in Note 20.
	Issuance of Preferred Stock to George J. Coates
	Shares of Series A Preferred Stock awarded to George J. Coates during the year ended December 31, 2013 is discussed in detail in Note 15.
	Personal Guaranty and Stock Pledge
	George J. Coates has pledged certain of his shares of common stock of the Company to the extent required by the lender and provided a personal guaranty as additional collateral for a mortgage loan on the Company’s headquarters facility.
	Compensation and Benefits Paid
	The approximate amount of compensation and benefits, all of which were approved by the board, paid to George J. Coates, Gregory Coates and Bernadette Coates, exclusive of stock-based compensation for restricted shares of common stock awarded to George J. Coates and non-cash, stock-based compensation for employee stock options granted to George J. Coates and Gregory Coates, for the years ended December 31, 2013 and 2012, is summarized as follows:
			2013		2012
	George J. Coates (a)(b)(c)(d)(e)(f)(g)		$	29,000	$	277,000
	Gregory Coates (a)(h)			169,000		173,000
	Bernadette Coates (i)			15,000		77,000
		(a)	Includes compensation paid in 2012 for vacation earned but not taken.
		(b)	For the year ended December 31, 2013, George J. Coates earned additional base compensation of $231,000, payment of which is being deferred until the Company has sufficient working capital. This amount is included in deferred compensation in the accompanying balance sheet at December 31, 2013.
		(c)	During the year ended December 31, 2013, George J. Coates was awarded 14,142,085 unregistered shares of the Company’s common stock for anti-dilution protection related to new shares of common stock issued in 2013. The estimated value of these shares, based on the closing trading price of the stock on the dates of issuance was $430,000 which was charged to stock-based compensation expense for the the year ended December 31, 2013. On August 30, 2013, these shares were voluntarily returned to the Company for cancellation, upon which the shares were restored to the authorized, but unissued status.
		(d)	In January 2013, the Company issued 20,895,046 unregistered shares of its common stock to George J. Coates in satisfaction of a deferred compensation liability consisting of 20,275,046 shares for anti-dilution protection for the year ended December 31, 2012 and a 620,000 share stock award originally granted in 2011. The value of these shares, based on the closing trading price on the dates of the anti-dilution or the date of the stock award was $1,761,000, of which $1,674,000 and $87,000 was charged to stock-based compensation expense during the years ended December 31, 2012 and 2011, respectively. On August 30, 2013, these shares were voluntarily returned to the Company for cancellation, upon which the shares were restored to the authorized, but unissued status.
		(e)	During the year ended December 31, 2013, George J. Coates was awarded 68,590 unregistered shares of the Company’s Series A Preferred Stock for anti-dilution protection related to new shares of common stock issued in 2013. The estimated value of these shares was $170,000.
		(f)	Excludes compensation in 2012 consisting of 20,275,046 restricted shares of common stock awarded to George J. Coates pursuant to an anti-dilution arrangement in effect during the year ended December 31, 2012. Of this amount, 18,593,313 shares of common stock were initially issued throughout 2012. In December 2012, these shares were cancelled and restored to unissued status. The entire 20,275,046 shares of common stock awarded in 2012 were then reissued in January 2013. The estimated fair value of these shares was $1,674,000, which amount is included in stock-based compensation expense in the accompanying statement of operations for the year ended December 31, 2012.
		(g)	Excluded from the amounts reported above for 2012 are 1,815,000 stock options with an exercise price of $0.06 per share. The estimated fair value of these stock options on the date of grant was $116,000.
		(h)	During the year ended December 31, 2012, the Company recorded stock-based compensation expense amounting to $252,000 in connection with employee stock options granted to Gregory Coates in 2011.
		(i)	For the year ended December 31, 2013, Bernadette Coates earned additional base compensation of $57,000, payment of which is being deferred until the Company has sufficient working capital. This amount is included in deferred compensation in the accompanying balance sheet at December 31, 2013.
	During the year ended December 31, 2013 and 2012, Barry C. Kaye, Treasurer and Chief Financial Officer was paid compensation of $40,000 and $67,000, respectively. For the year ended December 31, 2013, Mr. Kaye earned compensation of $120,000 which was not paid and is being deferred until the Company has sufficient working capital to remit payment to him. This amount is included in accounts payable and accrued liabilities in the accompanying balance sheet at December 31, 2013.

Contractual_Obligations_and_Co

Contractual Obligations and Commitments	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
CONTRACTUAL OBLIGATIONS AND COMMITMENTS	'
	25. CONTRACTUAL OBLIGATIONS AND COMMITMENTS
	The following table summarizes our contractual obligations and commitments at December 31, 2013:
				Due Within
		Total		2014		2015		2016
	Mortgage loan payable	$	1,513,000	$	1,513,000	$	-	$	-
	Promissory notes to related parties		603,000		603,000		-		-
	Convertible promissory notes		272,000		272,000		-		-
	Finance lease obligation		144,000		50,000		72,000		22,000
	Settlement of litigation		85,000		75,000		10,000		-
	10% promissory note		10,000		10,000		-		-
	Total	$	2,627,000	$	2,523,000	$	82,000	$	22,000
	Total non-cash compensation cost related to nonvested stock options at December 31, 2013 that has not been recognized was $4,000. This compensation expense will be recognized in the future over a remaining weighted average period of approximately 11 months.

Litigation_and_Contingencies

Litigation and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
LITIGATION AND CONTINGENCIES	'
	26. LITIGATION AND CONTINGENCIES
	Mark D. Goldsmith, a former executive of the Company, filed a lawsuit against the Company in January 2008 in which he asserted that the Company was liable to him for breach of an employment contract. On August 30, 2013, the parties executed a settlement agreement. The settlement provides that the Company pay the plaintiff $125,000 in five installments of $40,000, $25,000, $25,000, $25,000 and $10,000 due on November 28, 2013 and the 15th day of March 2014, June 2014, September 2014 and February 2015, respectively. The parties also executed mutual releases. The remaining unpaid balance of the settlement of $85,000 is included in accounts payable and accrued liabilities on the accompanying balance sheet at December, 2013. In the event that the Company is delinquent in the payment of any installment, the total amount of the judgment may be increased up to $200,000.
	The Company is not a party to any other litigation that is material to its business.

Recently_Issued_Accounting_Sta

Recently Issued Accounting Standard	12 Months Ended
	Dec. 31, 2013
Recently Issued Accounting Standard [Abstract]	'
RECENTLY ISSUED ACCOUNTING STANDARD	'
	27. RECENTLY ISSUED ACCOUNTING STANDARD
	In July 2013, the Financial Accounting Standards Board issued Accounting Standards Update No. 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” This update requires that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, unless the net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under applicable tax law or if the company does not intend to use the tax benefit towards the settlement of a disallowed tax position, if any.
	This standard will become effective for interim periods and fiscal years beginning on or after December 15, 2013. Adoption of this standard is not expected to have a material effect on the Company’s financial statements.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	28. SUBSEQUENT EVENTS
	Private Sales of Shares of Common Stock and Common Stock Warrants
	Subsequent to year end, the Company issued 7,339,286 unregistered, restricted shares of common stock, 6,625,000 common stock warrants to purchase one share of restricted common stock at a price per share of $0.04 and 714,286 common stock warrants to purchase one share of restricted common stock at a price per share of $0.035 to the son of Dr. Richard W. Evans, a director in consideration for $290,000. This transaction was a private sale of unregistered, restricted securities.
	Issuance of Convertible Note
	Subsequent to year-end, the Company entered into an agreement whereby it is permitted to issue in a series of tranches up to $100,000 of convertible promissory notes which bear interest at 12% per annum and mature on the one year anniversary of the notes. In January 2014, the Company issued a $35,000 principle amount convertible promissory note under this arrangement and received cash proceeds of $33,333. The arrangement provides for a 5% original issue discount on the principal amount of each tranche, which is netted against the amount funded to the Company. The promissory note may be prepaid at any time within the first 180 days with a 30% prepayment penalty. The lender may convert the promissory notes into shares of the Company’s common stock at any time beginning 180 days after the date of funding. The conversion rate shall be equal to the lesser of $0.05 per share or 70% of the lowest trade price of the common stock during the 20 consecutive trading days prior to the date of conversion. The Company has reserved 6.5 million shares of its unissued common stock for potential conversion of the convertible note.
	Conversion of Convertible Promissory Notes
	Subsequent to year-end, $55,000 principal amount of the 8% convertible promissory notes, including accrued interest thereon was converted by the holder into 2,059,138, unregistered shares of the Company’s common stock.
	Subsequent to year-end, $58,000 principal amount of the 12% convertible promissory notes, including accrued interest thereon was converted by the holder into 3,050,000, unregistered shares of the Company’s common stock.
	Shares of Common Stock Sold to Dutchess Opportunity Fund II, LP
		Subsequent to year-end, the Company sold 2,561,713 registered shares of its common stock to Dutchess under an equity line of credit and received cash of $102,000 which was used for working capital purposes.
	Issuance of Anti-dilution shares to George J. Coates
	Subsequent to year end, the Company issued 20,708 shares of Series A Preferred Stock to Mr. Coates representing anti-dilution shares related to newly issued shares of common stock. The estimated fair value of these shares was $52,000.
	Partial Repayment of 17% Promissory Notes Issued to Related Parties
	Subsequent to year-end, Company partially repaid 17% promissory notes due to George J. Coates and Bernadette Coates amounting $35,000 and $15,000, respectively.
	Deferred Compensation
	As of March 26, 2014, George J. Coates, Barry C. Kaye and Bernadette Coates agreed to additional deferral of their compensation amounting to $58,000, $10,000 and $16,000, respectively, bringing their total deferred compensation to $288,000, $130,000 and $72,000, respectively.
	Designation of Series B Convertible Preferred Stock
	In February 2014, the board of directors designated 1,000,000 shares of authorized shares of preferred stock as Series B Convertible Preferred Stock, par value $0.001 per share. The Series B Convertible Preferred Stock does not earn any dividends and may be converted at the option of the holder at any time beginning on the second annual anniversary date after the date of issuance into One Thousand restricted shares of the Corporation’s common stock. Holders of the Series B Preferred Stock are entitled to one thousand votes per share of Series B Preferred Stock held on all matters brought before the shareholders for a vote.
	In the event that either (i) the Company enters into an underwriting agreement for a secondary public offering of securities, or (ii) a change in control of the Company is consummated representing 50% more of the then outstanding shares of Company’s common stock, plus the number of shares of common stock into which any convertible preferred stock is convertible, regardless of whether or not such shares are otherwise eligible for conversion, then the Series B Preferred Stock may be immediately converted at the option of the holder into one thousand restricted shares of the Company’s common stock.
	As of March 26, 2014, there were no shares of Series B Preferred Stock issued or outstanding.

The_Company_and_Summary_of_Sig1

The Company and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
The Company and Summary of Significant Accounting Policies [Abstract]	'
Nature of Organization	'
	Nature of Organization
	Coates International, Ltd. is a Delaware corporation organized in October 1991 as successor-in-interest to a Delaware corporation of the same name incorporated in August 1988.  Coates International, Ltd. operates in Wall Township, New Jersey.
	The Company has acquired the exclusive licensing rights for the Coates spherical rotary valve (“CSRV®”) system technology in North America, Central America and South America (the “CSRV® License”). The CSRV® system technology has been developed over a period of more than 20 years by the Company’s founder George J. Coates and his son Gregory Coates. The CSRV® system technology is adaptable for use in piston-driven internal combustion engines of many types and has been patented in the United States and numerous countries throughout the world.
		The CSRV® system technology is designed to replace the intake and exhaust conventional “poppet valves” currently used in almost all piston-driven, automotive, truck, motorcycle, marine and electric power generator engines, among others. Unlike conventional valves which protrude into the engine cylinder, the CSRV® system technology utilizes spherical valves that rotate in a cavity formed between a two-piece cylinder head. The CSRV® system technology utilizes significantly fewer moving parts than conventional poppet valve assemblies. As a result of these design improvements, management believes that engines incorporating the CSRV® system technology (“Coates Engines”) will last significantly longer and will require less lubrication over the life of the engine, as compared to conventional engines. In addition, CSRV® Engines can be designed with larger openings into the engine cylinder than with conventional valves so that more fuel and air can be inducted into, and expelled from, the cylinder in a shorter period of time.  Larger valve openings permit higher revolutions-per-minute (RPM’s) and permit higher compression ratios with lower combustion chamber temperatures, allowing the Coates Engine to produce more power than equivalent conventional engines. The extent, to which higher RPM’s, greater volumetric efficiency and thermal efficiency can be achieved with the CSRV® system technology, is a function of the engine design and application.
Hydrogen Reactor Technology Owned by George J. Coates	'
	Hydrogen Reactor Technology Owned by George J. Coates
		George J. Coates has developed a hydrogen reactor, which rearranges H2O water molecules into HOH molecules also known as Hydroxy-Gas. The Hydroxy-Gas produced by the hydrogen reactor is then harvested for use as a type of fuel. Mr. Coates is continuing with development of this technology to enable the harvested Hydroxy-Gas to be utilized as the fuel source to power our patented CSRV® engines. Mr. Coates is continuing with research and development of the next application of this technology in an attempt to power larger, industrial engines. If successful, this application will only require a ready supply of water and would be suitable for stationary engines and generators. Conventional internal combustion engines employing poppet valve assemblies require lubrication and would experience excessive heat and friction if powered with Hydroxy-Gas. This, in turn, would cause the engines to burn out in a rather short period of time. The materials and components of the CSRV® engines do not require such lubrication and are designed to operate relatively trouble-free on Hydroxy-Gas as the engine fuel. There can be no assurance that this technology can be developed successfully, or that if developed, it will be feasible to penetrate the internal combustion engine market with this technology. Applications for patent protection of this technology will be filed upon completion of the research and development. At this time, no arrangements have been made between the Company and George J. Coates, owner of the technology, regarding licensing of the hydrogen reactor. Accordingly, the Company does not have any rights to manufacture, use, sell and distribute the Hydrogen Reactor technology, should it become commercially feasible to manufacture and distribute products powered by the Hydroxy-Gas fuel. The Company has been and continues to be responsible for all costs incurred related to the development of this technology.
Basis of Presentation	'
	Basis of Presentation
		The accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and rules and regulations of the Securities and Exchange Commission (the “SEC”).
		Since the Company’s inception, the Company has been responsible for the development costs of the CSRV® technology in order to optimize the value of the licensing rights and has incurred related operational costs, the bulk of which have been funded primarily through cash generated from sales of stock, short term convertible promissory notes, capital contributions, loans made by George J. Coates, Bernadette Coates, his spouse and certain directors, fees received from research and development of prototype models, licensing fees and a small number of CSRV® engine generator sales. The Company has incurred substantial cumulative losses from operations since its inception. Losses from operations are expected to continue until the Coates Engines are successfully introduced into and accepted in the marketplace, or the Company receives substantial licensing revenues. These losses from operations were substantially related to research and development of the Company’s intellectual property rights, patent filing and maintenance costs and general and administrative expenses.
	As shown in the accompanying financial statements, the Company has incurred recurring losses from operations and, as of December 31, 2013, had a stockholders’ deficiency of ($3,232,000). The Company will be required to renegotiate the terms of an extension of a $1,513,000 mortgage loan which matures in July 2014, or successfully refinance the property with another mortgage lender, if possible. Failure to do so could adversely affect the Company’s financial position and results of operations. In addition, the current economic environment, which is characterized by tight credit markets, investor uncertainty about how to safely invest their funds and low investor confidence, has introduced additional risk and difficulty to the Company’s challenge to secure needed additional working capital. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management has instituted a cost control program intended to restrict variable costs to only those expenses that are necessary to complete its activities related to entering the production phase of operations, develop additional commercially feasible applications of the CSRV® system technology, seek additional sources of working capital and cover general and administrative costs in support of such activities. The Company has been actively undertaking efforts to secure new sources of working capital. At the December 31, 2013, the Company had negative working capital of ($5,059,000) compared with negative working capital of ($5,893,000) at the end of 2012.
	During the years ended December 31, 2013 and 2012, the Company raised $917,000 and $1,123,000, respectively, of new working capital from the following:
	Description		2013		2012
	Issuance of convertible promissory notes		$	398,000	$	244,000
	Sales of common stock under equity line of credit			156,000		259,000
	Proceeds from sale/leaseback of equipment			133,000		-
	Sales of shares of common stock and warrants to the son of a director			125,000		355,000
	Issuance of promissory notes to related parties, net of repayments			95,000		230,000
	Proceeds from exercise of common stock warrants			10,000		-
	Sales of common stock to a director			-		35,000
			$	917,000	$	1,123,000
	In the fourth quarter of 2011, the Company identified cracks on the lower engine heads of its Gen Sets that resulted from a defect in the manufacturing by one of its suppliers. Based on testing of the Gen Set to confirm the Company’s resolution of this problem, management believes it has determined the cause of this cracked head condition. The Company has been endeavoring to raise sufficient working capital, in order to procure new cast-steel head castings to resolve the cracked head problems with the engines originally shipped to Almont. Thereafter, we will undertake field testing of the Gen Sets, after which, we will begin ramp-up production.
	The Company continues to actively seek out new sources of working capital; however, there can be no assurance that it will be successful in these efforts. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
	Certain amounts included in the accompanying financials statements for the year ended December 31, 2012 have been reclassified in order to make them comparable to the amounts presented for the year ended December 31, 2013.
Majority-Owned Subsidiary	'
	Majority-Owned Subsidiary
	CIL is currently the majority shareholder of Coates Hi-Tech Engines, Ltd. (“Coates Hi-Tech”), a Delaware corporation which was formed in July 2012. It has not commenced operations and has no assets. Accordingly, this subsidiary has not been consolidated with the accounts of CIL.
	For the year ended December 31, 2012, the financial statements of CIL were previously consolidated with the accounts of Coates Oklahoma Engine Manufacturing, Ltd. (“Coates Oklahoma”). In May 2013, Coates Oklahoma was shuttered and has since been formally dissolved. There were no outstanding obligations or expenses in dissolving this company. Accordingly, the financial statements for the year ended December 31, 2012 have been revised to present Coates International, Ltd. on an unconsolidated basis. There are no significant differences in the reported financial position or results of operations reported in the revised financial statements.
Revenue Recognition	'
	Revenue Recognition
	Sales and cost of sales are recognized at the time of shipment, provided the risk of loss has transferred to the customer and collection of the sales price is reasonably assured. Shipping arrangements and costs are the responsibility of the customer.
	Revenue from research and development activities is recognized when collection of the related revenues is reasonably assured and, when applicable, in accordance with Accounting Standards Update No. 2010-17, “Milestone Method of Revenue Recognition, a consensus of the FASB Emerging Issues Task Force”. This standard provides guidance on defining a milestone and permits recognition of revenue from research and development that is contingent upon achievement of one or more specified milestones defined in the research and development arrangements which meet specified criteria for such revenue recognition.
	Unearned revenue represents a deposit from a customer for a CSRV® Gen Set order. Revenue is recognized as described above.
	License deposits, which are non-refundable, were received from the granting of sub-licenses and are recognized as earned, generally commencing upon the completion of certain tests  of the CSRV® products and acceptance by the licensee.  At that time, license revenue will be recognized ratably over the period of time that the sub-license has been granted using the straight-line method.  Upon termination of a sub-license agreement, non-refundable license deposits, less any costs related to the termination of the sub-license agreement, are recognized as revenue. Revenue from research and development activities is recognized when earned and realization is reasonably assured, provided that financial risk has been transferred from the Company to its customer.
	The Company commenced shipping production units to Almont under the Canadian Sublicense in April 2011 and began recognizing the license deposit of $300,000 on the Canadian Licensee as revenue on a straight-line basis over the approximate remaining life through 2027 of the last CSRV® technology patent in force, at that date.
Research and Development	'
	Research and Development
	Research and development costs are expensed when incurred. For the year ended December 31, 2012, the Company charged $115,000 to expense for the estimated remediation costs of previously sold Gen Sets, that were determined to have cracked heads.
Intellectual Property	'
	Intellectual Property
	Under a licensing agreement with George J. Coates and Gregory Coates, the Company obtained the rights to manufacture, use and sell the CSRV® engine technology throughout the territory defined as the Western Hemisphere. In accordance with GAAP, the Company is not permitted to record a value for this intellectual property because it was obtained from principal stockholders, and, accordingly this intangible asset is not reflected in the accompanying financial statements.
Licensing Costs	'
	Licensing Costs
	Under the CSRV® Licensing Agreement for the CSRV® engine technology, the Company is responsible for all costs in connection with applying for, obtaining and maintenance of patents to protect the CSRV® system technology. Such costs are expensed as incurred.
Advertising Costs	'
	Advertising Costs
	Advertising costs, which are included in general and administrative expenses, are expensed when incurred.  Advertising expense amounted to $3,000 and $5,000 for the years ended December 31, 2013 and 2012, respectively.
Stock-Based Compensation	'
	Stock-Based Compensation
	Compensation expense relating to stock-based payments is recognized as an expense using the fair value measurement method. Under the fair value method, the estimated fair value of awards to employees is charged to income on a straight-line basis over the requisite service period, which is the earlier of the employee’s retirement eligibility date or the vesting period of the award. The Company incurs non-cash, stock-based compensation expense for stock options awarded and for awards of restricted shares of its common stock under it 2006 Stock Option and Incentive Plan.
Deferred Compensation	'
	Deferred Compensation
	Deferred compensation represents salaries of George J. Coates and Bernadette Coates earned in 2013, but not paid in order to preserve the Company’s working capital. The Company intends to repay these amounts at such time that it has sufficient working capital and after the related party notes to George J. Coates and Bernadette Coates have been repaid with interest thereon.
Inventory	'
	Inventory
	Inventory consists of raw materials and work-in-process, including overhead and is stated at the lower of cost or market determined by the first-in, first-out method. Inventory items designated as obsolete or slow moving are reduced to net realizable value. Market value is determined using current replacement cost.
Property, Plant and Equipment	'
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost.  Depreciation is computed using the straight-line method over the estimated useful life of the assets: 40 years for buildings and building improvements, 3 to 7 years for machinery and equipment and 5 to 10 years for furniture and fixtures.  Repairs and maintenance expenditures, which do not extend the useful lives of the related assets, are expensed as incurred.
	In the event that facts and circumstances indicate that long-lived assets may be impaired, an evaluation of recoverability is performed. Should such evaluation indicate that there has been an impairment of one or more long-lived assets, the cost basis of such assets would be adjusted accordingly, at that time.
Income Taxes	'
	Income Taxes
	Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized and are adjusted when conditions indicate that deferred assets will be realized. Income tax expense (benefit) is the tax payable or refundable for the period, plus or minus the change during the period in deferred tax assets and liabilities.
	The Company evaluates any uncertain tax positions for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes. In the event recognition of an uncertain tax position is indicated, the Company measures the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. This process of evaluating and estimating uncertain tax positions and tax benefits requires the consideration of many factors, which may require periodic adjustments and which may not accurately forecast actual outcomes. Interest and penalties, if any, related to tax contingencies would be included in income tax expense.
Loss per Share	'
	Loss per Share
	Basic net loss per share is based on the weighted average number of common shares outstanding without consideration of potentially dilutive shares of common stock. There were no shares of preferred stock outstanding with rights to share in the Company’s net income during the years ended December 31, 2013 and 2012. Diluted net income per share is based on the weighted average number of common and potentially dilutive common shares outstanding, when applicable.
Use of Estimates	'
	Use of Estimates
	The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These significant estimates include determining the fair value of convertible promissory notes containing embedded derivatives and variable conversion rates, determining a value for Series A Preferred Stock issued and certain limited anti-dilution rights granted to George J. Coates as more fully described in Note 15, assigning useful lives to the Company’s property, plant and equipment, determining an appropriate amount to reserve for obsolete and slow moving inventory, estimating a valuation allowance for deferred tax assets, assigning expected lives to, and estimating the rate of forfeitures of, stock options granted and selecting a trading price volatility factor for the Company’s common stock in order to estimate the fair value of the Company’s stock options on the date of grant or other appropriate measurement date. Actual results could differ from those estimates.

The_Company_and_Summary_of_Sig2

The Company and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
The Company and Summary of Significant Accounting Policies [Abstract]	'
Summary of new working capital	'
	Description	2013		2012
	Issuance of convertible promissory notes	$	398,000	$	244,000
	Sales of common stock under equity line of credit		156,000		259,000
	Proceeds from sale/leaseback of equipment		133,000		-
	Sales of shares of common stock and warrants to the son of a director		125,000		355,000
	Issuance of promissory notes to related parties, net of repayments		95,000		230,000
	Proceeds from exercise of common stock warrants		10,000		-
	Sales of common stock to a director		-		35,000
		$	917,000	$	1,123,000

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory [Abstract]	'
Summary of inventory	'
		2013			2012
	Raw materials	$	440,000		$	439,000
	Work-in-process		59,000			59,000
	Finished goods		-			-
	Less: Reserve for obsolescence		(387,000	)		(387,000	)
	Total	$	112,000		$	111,000

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Summary of Property, plant and equipment	'
		2013			2012
	Land	$	1,235,000		$	1,235,000
	Building		964,000			964,000
	Building improvements		83,000			83,000
	Machinery and equipment		658,000			658,000
	Furniture and fixtures		39,000			39,000
			2,979,000			2,979,000
	Less:  Accumulated depreciation		(799,000	)		(737,000	)
	Total	$	2,180,000		$	2,242,000

Accounts_Payable_and_Accrued_L1

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Account Payable and Accrued Liabilities [Abstract]	'
Summary of accounts payable and accrued liabilities	'
		2013		2012
	Legal and professional fees	$	1,388,000	$	1,240,000
	General and administrative expenses		301,000		149,000
	Accrued interest expense		264,000		118,000
	Accrued compensation and benefits		196,000		175,000
	Research and development costs		115,000		115,000
	Total	$	2,264,000	$	1,797,000

Convertible_Promissory_Notes_a1

Convertible Promissory Notes and Embedded Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2013
Convertible Promissory Notes and Embedded Derivative Liability [Abstract]	'
Convertible promissory notes and embedded derivative liability	'
		Principal Amount										Unamortized Discount				Embedded
																Derivative Liability
	Date Issued	December 31,		December 31,		Nominal			Effective			December 31,		December 31,		December 31,		December 31,
		2013		2012		Interest Rate			Interest Rate(1)			2013		2012		2013		2012
	12/11/13	$	28,000		N/A		10	%		134	%	$	22,000		N/A	$	43,000		N/A
	12/10/13		28,000		N/A		12	%		117	%		19,000		N/A		45,000		N/A
	12/9/13		28,000		N/A		10	%		134	%		22,000		N/A		43,000		N/A
	11/27/13		32,000		N/A		8	%		133	%		25,000		N/A		33,000		N/A
	10/11/13		47,000		N/A		8	%		147	%		31,000		N/A		48,000		N/A
	8/14/13		28,000		N/A		12	%		147	%		14,000		N/A		45,000		N/A
	8/8/13		53,000		N/A		8	%		147	%		14,000		N/A		53,000		N/A
	6/4/13		28,000		N/A		12	%		92	%		-		N/A		45,000		N/A
	3/21/13		-		N/A		12	%		76	%		-		N/A		12,000		N/A
	11/23/12		N/A	$	33,000		8	%		101	%		N/A	$	17,000		N/A	$	41,000
	9/24/12		N/A		32,000		8	%		122	%		N/A		14,000		N/A		41,000
	8/6/12		N/A		43,000		8	%		142	%		N/A		12,000		N/A		53,000
	6/12/12		N/A		12,000		8	%		142	%		N/A		-		N/A		-
		$	272,000	$	120,000							$	147,000	$	43,000	$	367,000	$	135,000
	(1) The effective interest rate reflects the rate required to fully amortize the unamortized discount over the six-month period until the Notes become convertible.

Income_Loss_Per_Share_Tables

Income (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Income (Loss) Per Share [Abstract]	'
Schedule of potentially issuable shares of common stock	'
	Description		Number of		Exercise			Number		Number
			Underlying		Price			Vested		Non-Vested
			Shares of
			Common
			Stock
	Common stock options			100,000	$	0.042			-		100,000
	Common stock options			5,607,000		0.06			5,607,000		-
	Common stock options			1,800,000		0.24			1,800,000		-
	Common stock options			2,000,000		0.25			2,000,000		-
	Common stock options			50,000		0.39			50,000		-
	Common stock options			360,000		0.4			360,000		-
	Common stock options			100,000		0.43			100,000		-
	Common stock options			1,750,000		0.44			1,750,000		-
	Common stock options			30,000		1			30,000		-
	Common stock warrants			500,000		0.02			N/A		N/A
	Common stock warrants			666,667		0.0225			N/A		N/A
	Common stock warrants			1,000,000		0.025			N/A		N/A
	Common stock warrants			333,333		0.03			N/A		N/A
	Common stock warrants			2,000,001		0.035			N/A		N/A
	Common stock warrants			500,000		0.04			N/A		N/A
	Common stock warrants			333,333		0.045			N/A		N/A
	Common stock warrants			400,000		0.05			N/A		N/A
	Common stock warrants			2,181,819		0.055			N/A		N/A
	Common stock warrants			2,000,000		0.06			N/A		N/A
	Common stock warrants			4,269,838		0.0625			N/A		N/A
	Common stock warrants			571,429		0.07			N/A		N/A
	Common stock warrants			666,666		0.09			N/A		N/A
	Common stock warrants			416,667		0.12			N/A		N/A
	Common stock warrants			1,200,000		0.25			N/A		N/A
	Common stock warrants			833,333		0.27			N/A		N/A
	Common stock warrants			333,333		0.3			N/A		N/A
	Common stock warrants			153,846		0.325			N/A		N/A
	Common stock warrants			1,028,570		0.35			N/A		N/A
	$10,000, 10% Convertible promissory note			22,222		0.45			N/A		N/A
	8% Convertible promissory notes			6,445,105		(1	)		N/A		N/A
	10% Convertible promissory notes			3,160,920		(1	)		N/A		N/A
	12% Convertible promissory notes			5,156,232		(1	)		N/A		N/A
	Total			45,970,314
		-1	The principal amount of convertible promissory notes outstanding at December 31, 2013, was $272,000. Under the convertible terms of these notes, the number of share of common stock into which these notes are convertible is variable because the conversion rates of the notes are based on the trading price of the common stock over a defined a number of trading days leading up to the conversion date during a defined conversion rate pricing period. The actual number of shares underlying these convertible instruments will likely vary from the number assumed above. The number of shares underlying these convertible notes was determined based on the defined conversion rates of the various convertible notes, assuming conversion had occurred as of December 31, 2013.
	Description		Number of		Exercise			Number		Number
			Underlying		Price			Vested		Non-Vested
			Shares of
			Common
			Stock
	Common stock options			5,607,000	$	0.06			-		5,607,000
	Common stock options			1,800,000		0.24			1,800,000		-
	Common stock options			2,000,000		0.25			2,000,000		-
	Common stock options			50,000		0.39			50,000		-
	Common stock options			360,000		0.4			360,000		-
	Common stock options			100,000		0.43			100,000		-
	Common stock options			1,750,000		0.44			1,750,000		-
	Common stock options			30,000		1			30,000		-
	Common stock warrants			333,333		0.045			N/A		N/A
	Common stock warrants			400,000		0.05			N/A		N/A
	Common stock warrants			2,181,819		0.055			N/A		N/A
	Common stock warrants			2,000,000		0.06			N/A		N/A
	Common stock warrants			4,269,838		0.0625			N/A		N/A
	Common stock warrants			571,429		0.07			N/A		N/A
	Common stock warrants			666,666		0.09			N/A		N/A
	Common stock warrants			416,667		0.12			N/A		N/A
	Common stock warrants			1,200,000		0.25			N/A		N/A
	Common stock warrants			833,333		0.27			N/A		N/A
	Common stock warrants			333,333		0.3			N/A		N/A
Common stock warrants			153,846		0.325			N/A		N/A
Common stock warrants			1,028,570		0.35			N/A		N/A
$10,000, 10% Convertible promissory note			22,222		0.45			N/A		N/A
8% Convertible promissory notes			10,550,214		(1	)		N/A		N/A
Total			36,658,270
	-1	The principal amount of convertible promissory notes outstanding, none of which were eligible for conversion at December 31, 2012, was $120,000. The conversion rate is variable as it is equal to the average of the three lowest closing bid prices during the ten trading days prior to the date of conversion. The actual number of shares underlying these convertible instruments will likely vary from the number assumed above. The number of shares underlying these convertible notes was determined based on the three lowest closing bid prices during the ten trading days prior to December 31, 2012.

Stock_Options_Tables

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2013
Stock Options [Abstract]	'
Summary of activity in company's stock option plan	'
		Exercise				Number				Weighted		Number		Weighted		Weighted
		Price Per				Outstanding				Average		Exercisable		Average		Average
		Share								Remaining				Exercise		Fair Value
										Contractual Life				Price		Per Stock Option
																at Date of
																Grant
	Balance, 1/1/12			0.25 -1.00				6,090,000			12		2,290,000		0.32		0.28
	Stock options granted			0.06				5,607,000			15		-		0.06		0.06
	Vested			0.24				-			14		1,800,000		0.24		0.24
	Vested			0.25				-			14		2,000,000		0.25		0.24
	Balance, 12/31/12			0.600 -1.000				11,697,000			12		6,090,000		0.194		0.18
	Stock options granted			0.042				100,000			15		-		0.042		0.042
	Vested			0.24				-			14		5,607,000		0.24		0.24
	Balance, 12/31/13			0.042 – 1.000				11,797,000			12		11,697,000		0.193		0.179
Summary of assumptions used to determine weighted average fair value	'
	●	Historical stock price volatility		139% - 325%
	●	Risk-free interest rate		0.21%-4.64%
	●	Expected life (in years)		4
	●	Dividend yield		0
Summary of stock options outstanding	'
	Name		Title		Number of						Option
					Shares of				Exercise		Expiration
					Common Stock				Price per		Date
					Underlying				Share
					Stock Options
	George J. Coates		Chairman, Chief  Executive Officer and President			1,000,000	-1		$	0.44	10/23/21
						50,000	-1			0.43	11/4/24
						275,000	-1			0.4	11/17/25
						1,800,000	-1			0.25	7/25/26
						1,815,000	-1			0.06	6/24/27
	Gregory Coates		Director and President, Technology Division			500,000	-1			0.44	10/23/21
						1,800,000	-1			0.24	8/8/26
	Barry C. Kaye		Director, Treasurer and Chief Financial Officer			125,000	-1			0.44	10/18/21
						100,000	-2			0.042	12/11/28
	Dr. Frank J. Adipietro		Non-employee Director			25,000	-1			0.44	3/28/2022
						50,000	-1			0.43	11/3/24
						85,000	-1			0.4	11/17/25
						667,000	-1			0.06	6/24/27
	Dr. Richard W. Evans		Non-employee Director and Secretary			25,000	-1			0.44	3/28/2022
						50,000	-1			0.39	12/27/24
						200,000	-1			0.25	2/15/26
						3,125 000	-1			0.06	6/20/27
	Dr. Michael J. Suchar		Non-employee Director			25,000	-1			0.44	3/28/2022
	Richard Whitworth		Non-employee Director			25,000	-1			0.44	3/28/2022
	William Wolf. Esq.		Outside General Counsel			25,000	-1			0.44	4/4/2022
	Company Supplier		Company Supplier			30,000	-1			1	10/7/2015
		(1) These stock options are fully vested.
		(2) These options will fully vest in December 2014.

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Schedule of total deferred tax assets and valuation allowances	'
		2013			2012
	Current deferred tax asset - inventory reserve	$	195,000		$	195,000
	Non-Current Deferred Tax Assets:
	Net operating loss carryforwards		6,201,000			5,774,000
	Stock-based compensation expense		1,688,000			1,436,000
	Accrued liabilities not paid		481,000			492,000
	Deferred compensation not paid within 2.5 months		115,000			-
	Accrued interest on notes to related parties		115,000			64,000
	Total long-term deferred tax assets		8,600,000			7,766,000
	Total deferred tax assets		8,795,000			7,961,000
	Less: valuation allowance		(8,795,000	)		(7,961,000	)
	Net deferred tax assets	$	-		$	-
Schedule of differences in Income tax (benefit) provision	'
		2013			2012
	Federal tax provision (benefit) at the statutory rate		34	%		34	%
	State income tax provision (benefit), net of federal benefit		(2.7	)		(2.7	)
	Net change in net operating loss carryforwards		(15.5	)		(16.6	)
	Stock-based compensation expense		(9.1	)		(15.6	)
	Accrued interest not deductible for tax return purposes		(6.0	)		(1.2	)
	Deferred compensation not paid within 2.5 months		(4.2	)		-
	(Increase) Decrease in estimated fair value of embedded derivative liabilities		(3.1	)		2.9
	Provision for slow-moving and obsolete inventory		-			(2.1	)
	Accrued liabilities not deductible for tax return purposes		0.4			(1.1	)
	Officer’s life insurance		(0.2	)		-
	Total		(6.4	)		(2.4	)
	Valuation allowance		6.4			2.4
	Effective tax rate		0	%		0	%

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Summary of approximate amount of base compensation and benefits	'
		2013		2012
	George J. Coates (a)(b)(c)(d)(e)(f)(g)	$	29,000	$	277,000
	Gregory Coates (a)(h)		169,000		173,000
	Bernadette Coates (i)		15,000		77,000

Contractual_Obligations_and_Co1

Contractual Obligations and Commitments (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Contractual obligations and commitments	'
				Due Within
		Total			2014		2015		2016
	Mortgage loan payable	$	1,513,000		$	1,513,000	$	-	$	-
	Promissory notes to related parties		603,000			603,000		-		-
	Convertible promissory notes		272,000			272,000		-		-
	Finance lease obligation		144,000			50,000		72,000		22,000
	Settlement of litigation		85,000			75,000		10,000		-
	10% promissory note		10,000			10,000		-		-
	Total	$	2,627,000		$	2,523,000	$	82,000	$	22,000

The_Company_and_Summary_of_Sig3

The Company and Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Basis of Presentation [Abstract]	'	'
Issuance of convertible promissory notes	$398,000	$244,500
Sales of common stock under equity line of credit	155,506	258,722
Proceeds from sale/leaseback of equipment	132,550	'
Sales of shares of common stock and warrants to the son of a director	125,000	355,000
Issuance of promissory notes to related parties, net of repayments	95,000	230,000
Proceeds from exercise of common stock warrants	10,000	'
Sales of common stock to a director	'	35,000
New working capital	$917,000	$1,123,000

The_Company_and_Summary_of_Sig4

The Company and Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
The Company and Summary of Significant Accounting Policies (Textual)	'	'	'
Stockholder's deficiency	($3,231,617)	($3,937,287)	($1,751,291)
Mortgage loan payable	1,513,284	1,575,000	'
Negative working capital	-5,059,000	-5,893,000	'
New working capital	917,000	1,123,000	'
Mortgage loan maturity date	31-Jul-14	'	'
Estimated remediation costs	'	115,000	'
Advertising expense	3,000	5,000	'
License Deposits [Member]	'	'	'
The Company and Summary of Significant Accounting Policies (Textual)	'	'	'
License Deposits	$300,000	$300,000	'
Amortization Period	'Straight-line basis over the remaining life until 2027.	'	'
Building and Building Improvements [Member]	'	'	'
The Company and Summary of Significant Accounting Policies (Textual)	'	'	'
Estimated useful life of the assets	'40 years	'	'
Machinery and Equipment [Member] | Maximum [Member]	'	'	'
The Company and Summary of Significant Accounting Policies (Textual)	'	'	'
Estimated useful life of the assets	'7 years	'	'
Machinery and Equipment [Member] | Minimum [Member]	'	'	'
The Company and Summary of Significant Accounting Policies (Textual)	'	'	'
Estimated useful life of the assets	'3 years	'	'
Furniture and Fixtures [Member] | Maximum [Member]	'	'	'
The Company and Summary of Significant Accounting Policies (Textual)	'	'	'
Estimated useful life of the assets	'10 years	'	'
Furniture and Fixtures [Member] | Minimum [Member]	'	'	'
The Company and Summary of Significant Accounting Policies (Textual)	'	'	'
Estimated useful life of the assets	'5 years	'	'

Licensing_Agreement_and_Deferr1

Licensing Agreement and Deferred Licensing Costs (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Licensing Agreement and Deferred Licensing Costs (Textual)	'	'
Deferred licensing costs	$51,000	$55,000
Amortization expense	$4,000	$4,000

Agreements_Assigned_to_Almont_1

Agreements Assigned to Almont Energy, Inc. (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Generators
Agreements Assigned to Almont Energy, Inc. (Textual)	'
Additional fee under R&D Agreement	$5,000,000
License fee received under Canadian License	5,000,000
Licensing fee under US License	50,000,000
Down payment on US License to be paid by Almont Energy	1,000,000
Remaining balance of release payment	5,847,000
Percentage of money raised required to remit from future equity or debt transactions by Almont Energy	60.00%
Obligation under US license fee	49,000,000
Percentage of quarterly net profits payable	5.00%
US License Payment due date	19-Feb-16
Units projected to be purchased per year over next 5 years	11,000
Canadian License [Member]	'
Agreements Assigned to Almont Energy, Inc. (Textual)	'
Percentage of modified gross profit to be paid	5.00%
Amount to be added to gross profit to arrive at modified gross profit	400,000
Minimum annual number of generators to be purchased	120
Price per generator	159,000
Us License [Member]	'
Agreements Assigned to Almont Energy, Inc. (Textual)	'
Percentage of modified gross profit to be paid	2.50%
Amount to be added to gross profit to arrive at modified gross profit	$400,000
Minimum annual number of internal combustion engines	120

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Summary of inventory	'	'
Raw materials	$440,000	$439,000
Work-in-process	59,000	59,000
Finished goods	'	'
Less: Reserve for obsolescence	-387,000	-387,000
Total	$112,000	$111,000

Inventory_Detail_Textuals

Inventory (Detail Textuals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory (Textual)	'	'
Components and parts inventory, carrying value determined to be obsolete	'	$236,000
Reserve for slow-moving and obsolete inventory	$387,000	$387,000

License_Deposits_Details

License Deposits (Details) (License Deposits [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
License Deposits [Member]	'	'
License Deposits (Textual)	'	'
Sublicense deposit received as down payment on Canadian License	$300,000	$300,000
License deposit recognition term	'Straight-line basis over the remaining life until 2027.	'
Sublicensing fee revenue	$19,000	$19,000

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Summary of Property, plant and equipment	'	'
Property, plant and equipment, Gross	$2,979,000	$2,979,000
Less: Accumulated depreciation	-799,000	-737,000
Total	2,180,000	2,242,000
Land [Member]	'	'
Summary of Property, plant and equipment	'	'
Property, plant and equipment, Gross	1,235,000	1,235,000
Building [Member]	'	'
Summary of Property, plant and equipment	'	'
Property, plant and equipment, Gross	964,000	964,000
Building Improvements [Member]	'	'
Summary of Property, plant and equipment	'	'
Property, plant and equipment, Gross	83,000	83,000
Machinery and Equipment [Member]	'	'
Summary of Property, plant and equipment	'	'
Property, plant and equipment, Gross	658,000	658,000
Furniture and Fixtures [Member]	'	'
Summary of Property, plant and equipment	'	'
Property, plant and equipment, Gross	$39,000	$39,000

Property_Plant_and_Equipment_D1

Property, Plant and Equipment (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment (Textual)	'	'
Depreciation expense	$62,000	$61,000

Mortgage_Loan_Payable_Details

Mortgage Loan Payable (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Mortgage Loan Payable (Textual)	'	'
Mortgage loan payable, interest rate	7.50%	7.50%
Mortgage loan payable	$1,513,000	$1,575,000
Mortgage loan payment terms	'	'
	Monthly payments of interest, plus $5,000 which is being applied to the principal balance.
Interest expense	114,000	122,000
Maximum limit for prepayment of principal balance each year without penalty	$500,000	'
Percentage of prepayment penalty on outstanding loan amount	2.00%	'
Shares collateral for borrowed fund	5,000,000	'

Finance_Lease_Obligation_Detai

Finance Lease Obligation (Details) (Financel Lease Obligations [Member], USD $)	1 Months Ended	12 Months Ended
	Aug. 31, 2013	Dec. 31, 2013
Finance Lease Obligation Textual [Abstract]	'	'
Deposits on lease	$15,000	'
Transaction costs	5,000	'
Equipment, lease back period	'	'Over a 24-month period, with an option to extend the lease for an additional six months.
Monthly lease payment	8,000	'
Interest rate on lease	36.60%	'
Unamortized discount on finance lease obligation	20,000	'
Amortized period of interest expense	'	'Over the 30-month term of the lease.
Financial lease, interest expense	'	21,000
Paradigm Commercial Capital Group Corp [Member]	'	'
Finance Lease Obligation Textual [Abstract]	'	'
Cash proceeds for research and development and manufacturing equipment	$133,000	'

Accounts_Payable_and_Accrued_L2

Accounts Payable and Accrued Liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Summary of accounts payable and accrued liabilities	'	'
Legal and professional fees	$1,388,000	$1,240,000
General and administrative expenses	301,000	149,000
Accrued interest expense	264,000	118,000
Accrued compensation and benefits	196,000	175,000
Research and development costs	115,000	115,000
Total	$2,264,000	$1,797,000

Promissory_Notes_to_Related_Pa1

Promissory Notes to Related Parties (Details) (USD $)	12 Months Ended						1 Months Ended		1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2012	Dec. 31, 2012	Oct. 31, 2012	Jun. 30, 2012	Dec. 31, 2012
	Director		George J Coates [Member]	George J Coates [Member]	Bernadette Coates [Member]	Bernadette Coates [Member]	Dr. Richard W. Evans [Member]	Dr. Richard W. Evans [Member]	Dr. Frank J. Adipietro [Member]	Dr. Frank J. Adipietro [Member]	Dr. Frank J. Adipietro [Member]
Promissory Notes to Related Parties (Textual)	'	'	'	'	'	'	'	'	'	'	'
Cash proceeds from related party promissory notes	'	'	$105,000	$195,000	$68,000	$76,000	'	'	'	'	'
Promissory notes principal repayment	'	'	67,000	31,000	10,000	10,000	'	'	'	'	'
Promissory notes, principal outstanding	'	'	'	'	'	'	120,000	120,000	40,000	10,000	50,000
Promissory notes, interest rate	'	'	17.00%	17.00%	17.00%	17.00%	17.00%	17.00%	17.00%	17.00%	17.00%
Number of shares of common stock issued upon conversion of promissory note	'	'	'	'	'	'	2,000,000	'	473,372	166,667	'
Conversion price	$0.45	'	'	'	'	'	$0.06	'	'	$0.06	'
Number of directors	2	'	'	'	'	'	'	'	'	'	'
Promissory notes interest expense	130,000	78,000	'	'	'	'	'	'	'	'	'
Promissory notes unpaid accrued interest	$230,000	'	'	'	'	'	'	'	'	'	'

10_Convertible_Note_to_Related1

10% Convertible Note to Related Party (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Convertible Note To Related Party Textual [Abstract]	'
Conversion price	$0.45
Dr. Michael J. Suchar [Member] | 10% Convertible Note [Member]	'
Convertible Note To Related Party Textual [Abstract]	'
Interest Rate	10.00%
Conversion price	$0.45
Shares of common stock reserved for conversion of note	22,222
Remaining amount on notes	$10,000

Convertible_Promissory_Notes_a2

Convertible Promissory Notes and Embedded Derivative Liability (Details) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012
Debt Instrument [Line Items]	'		'
Principal Amount	$272,000		$120,000
Embedded Derivative Liability	367,000		135,000
Convertible Promissory Notes [Member]	'		'
Debt Instrument [Line Items]	'		'
Unamortized Discount	147,000		43,000
12/11/13 [Member]	'		'
Debt Instrument [Line Items]	'		'
Date Issued	11-Dec-13		'
Principal Amount	28,000		'
Nominal Interest Rate	10.00%		'
Effective Interest Rate(1)	134.00%	[1]	'
Unamortized Discount	22,000		'
Embedded Derivative Liability	43,000		'
12/10/13 [Member]	'		'
Debt Instrument [Line Items]	'		'
Date Issued	10-Dec-13		'
Principal Amount	28,000		'
Nominal Interest Rate	12.00%		'
Effective Interest Rate(1)	117.00%	[1]	'
Unamortized Discount	19,000		'
Embedded Derivative Liability	45,000		'
12/9/13 [Member]	'		'
Debt Instrument [Line Items]	'		'
Date Issued	9-Dec-13		'
Principal Amount	28,000		'
Nominal Interest Rate	10.00%		'
Effective Interest Rate(1)	134.00%	[1]	'
Unamortized Discount	22,000		'
Embedded Derivative Liability	43,000		'
11/27/13 [Member]	'		'
Debt Instrument [Line Items]	'		'
Date Issued	27-Nov-13		'
Principal Amount	32,000		'
Nominal Interest Rate	8.00%		'
Effective Interest Rate(1)	133.00%	[1]	'
Unamortized Discount	25,000		'
Embedded Derivative Liability	33,000		'
10/11/13 [Member]	'		'
Debt Instrument [Line Items]	'		'
Date Issued	11-Oct-13		'
Principal Amount	47,000		'
Nominal Interest Rate	8.00%		'
Effective Interest Rate(1)	147.00%	[1]	'
Unamortized Discount	31,000		'
Embedded Derivative Liability	48,000		'
8/14/13 [Member]	'		'
Debt Instrument [Line Items]	'		'
Date Issued	14-Aug-13		'
Principal Amount	28,000		'
Nominal Interest Rate	12.00%		'
Effective Interest Rate(1)	147.00%	[1]	'
Unamortized Discount	14,000		'
Embedded Derivative Liability	45,000		'
8/8/13 [Member]	'		'
Debt Instrument [Line Items]	'		'
Date Issued	8-Aug-13		'
Principal Amount	53,000		'
Nominal Interest Rate	8.00%		'
Effective Interest Rate(1)	147.00%	[1]	'
Unamortized Discount	14,000		'
Embedded Derivative Liability	53,000		'
6/4/13 [Member]	'		'
Debt Instrument [Line Items]	'		'
Date Issued	4-Jun-13		'
Principal Amount	28,000		'
Nominal Interest Rate	12.00%		'
Effective Interest Rate(1)	92.00%	[1]	'
Unamortized Discount	'		'
Embedded Derivative Liability	45,000		'
3/21/13 [Member]	'		'
Debt Instrument [Line Items]	'		'
Date Issued	21-Mar-13		'
Principal Amount	'		'
Nominal Interest Rate	12.00%		'
Effective Interest Rate(1)	76.00%	[1]	'
Unamortized Discount	'		'
Embedded Derivative Liability	12,000		'
11/23/12 [Member]	'		'
Debt Instrument [Line Items]	'		'
Date Issued	23-Nov-12		'
Principal Amount	'		33,000
Nominal Interest Rate	8.00%		'
Effective Interest Rate(1)	101.00%	[1]	'
Unamortized Discount	'		17,000
Embedded Derivative Liability	'		41,000
9/24/12 [Member]	'		'
Debt Instrument [Line Items]	'		'
Date Issued	24-Sep-12		'
Principal Amount	'		32,000
Nominal Interest Rate	8.00%		'
Effective Interest Rate(1)	122.00%	[1]	'
Unamortized Discount	'		14,000
Embedded Derivative Liability	'		41,000
8/6/12 [Member]	'		'
Debt Instrument [Line Items]	'		'
Date Issued	6-Aug-12		'
Principal Amount	'		43,000
Nominal Interest Rate	8.00%		'
Effective Interest Rate(1)	142.00%	[1]	'
Unamortized Discount	'		12,000
Embedded Derivative Liability	'		53,000
6/12/12 [Member]	'		'
Debt Instrument [Line Items]	'		'
Date Issued	12-Jun-12		'
Principal Amount	'		12,000
Nominal Interest Rate	8.00%		'
Effective Interest Rate(1)	142.00%	[1]	'
Unamortized Discount	'		'
Embedded Derivative Liability	'		'
[1]	The effective interest rate reflects the rate required to fully amortize the unamortized discount over the six-month period until the Notes become convertible.

Recovered_Sheet1

Convertible Promissory Notes And Embedded Derivative Liability (Details Textual) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Aug. 31, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2013

Promissory_Note

8% Convertible Promissory Note One [Member]

8% Convertible Promissory Note Two [Member]

8% Convertible Promissory Note One Two And Three [Member]

8% Convertible Promissory Note Three [Member]

10% Convertible Promissory Notes One [Member]

10% Convertible Promissory Notes Two [Member]

12% Convertible Promissory Note [Member]

12% Convertible Promissory Note [Member]

12% Convertible Promissory Note [Member]

12% Convertible Promissory Note [Member]

Convertible Promissory Notes and Embedded Derivative Liabilities (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

Estimated fair value of embedded derivative liabilities related to promissory notes outstanding, Description

'The estimated fair value of the embedded derivative liabilities related to promissory notes outstanding was measured as the aggregate estimated fair value, based on Level 2 inputs, which included average quoted daily yield curve rates on six-month and one-year treasury securities and the calculated 12-month historical volatility rate on the Company's common stock.

'

'

'

'

'

'

'

'

'

'

'

Promissory notes, interest rate

'

'

8.00%

8.00%

'

8.00%

10.00%

10.00%

12.00%

12.00%

12.00%

12.00%

Debt Instrument, Face Amount

$272,000

$120,000

$53,000

$47,000

'

$32,000

$28,000

$28,000

$28,000

$28,000

$67,000

$28,000

Proceeds from debt

'

'

50,000

45,000

'

30,000

25,000

25,000

25,000

25,000

60,000

25,000

Maturity date, description

'

'

'May 2014

'July 2014

'

'August 2014

'December 2014

'December 2014

'August 2014

'June 2014

'March 2014

'

Common stock , par value

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

Period after which conversion can exercise

'

'

'180 days

'180 days

'180 days

'180 days

'180 days

'180 days

'180 days

'180 days

'180 days

'180 days

Conversion price, description

'

'

'The Conversion Price shall be equal to 61% multiplied by the Variable Conversion Rate which is equal to the average of the three (3) lowest closing bid prices of the Common Stock during the ten (10) trading day period prior to the date of conversion.

'The Conversion Price shall be equal to 61% multiplied by the Variable Conversion Rate which is equal to the average of the three (3) lowest closing bid prices of the Common Stock during the ten (10) trading day period prior to the date of conversion.

'The Conversion Price shall be equal to 61% multiplied by the Variable Conversion Rate which is equal to the average of the three (3) lowest closing bid prices of the Common Stock during the ten (10) trading day period prior to the date of conversion.

'The Conversion Price shall be equal to 61% multiplied by the Variable Conversion Rate which is equal to the average of the three (3) lowest closing bid prices of the Common Stock during the ten (10) trading day period prior to the date of conversion.

'The conversion rate shall be equal to 58% of the lowest daily volume weighted average price ("VWAP") of the Company's common stock over the 18 trading days ending on the date of conversion.

'The conversion rate shall be equal to 58% of the lowest daily volume weighted average price ("VWAP") of the Company's common stock over the 18 trading days ending on the date of conversion.

'The conversion rate shall be equal to the lesser of $0.035 per share or 60% of the lowest trade price of the Company's common stock in the 25 trading days prior to the date of conversion.

'The conversion rate shall be equal to the lesser of $0.035 per share or 60% of the lowest trade price of the Company's common stock in the 25 trading days prior to the date of conversion.

'The conversion rate shall be equal to the lesser of $0.035 per share or 60% of the lowest trade price of the Company's common stock in the 25 trading days prior to the date of conversion.

'The conversion rate shall be equal to the lesser of $0.035 per share or 60% of the lowest trade price of the Company's common stock in the 25 trading days prior to the date of conversion.

Prepayment option, description

'

'

'The Company may, during the first 179 days the note is outstanding, prepay the 8% Note by paying 130% during the first 60 days, increasing in 5% increments each month to a maximum of 150% of the then outstanding unpaid principal, interest and any other amounts that might be due for penalties or any event of a default.

'The Company may, during the first 179 days the note is outstanding, prepay the 8% Note by paying 130% during the first 60 days, increasing in 5% increments each month to a maximum of 150% of the then outstanding unpaid principal, interest and any other amounts that might be due for penalties or any event of a default.

'

'The Company may, during the first 179 days the note is outstanding, prepay the 8% Note by paying 130% during the first 60 days, increasing in 5% increments each month to a maximum of 150% of the then outstanding unpaid principal, interest and any other amounts that might be due for penalties or any event of a default.

'

'

'

'

'

'

The Company may, during the first 179 days the note is outstanding, prepay the 8% Note by paying 130% during the first 60 days, increasing in 5% increments each month to a maximum of 150% of the then outstanding unpaid principal, interest and any other amounts that might be due for penalties or any event of a default.

Percentage of discounted conversion price accreted to interest

'

'

'

61.00%

61.00%

61.00%

'

'

'

'

'

'

Shares reserved for debt conversion

'

'

7,800,000

'

46,750,000

'

'

'

'

'

'

35,000,000

Maximum amount that can be borrowed

'

'

'

'

'

'

'

'

'

335,000

'

335,000

Original issue discount on principal amount

'

'

'

'

'

'

'

'

'

'

'

10.50%

Number of convertible promissory notes

8

'

'

'

'

'

'

'

'

'

'

'

Common shares issued upon conversion of debt

10,968,349

8,415,515

'

'

'

'

'

'

'

'

'

2,750,000

Principal amount of debt, including accrued interest converted into shares of common stock

204,000

293,000

'

'

'

'

'

'

'

'

'

'

Other (expense) income resulting from the change in the estimated fair value of the embedded derivative liabilities

-210,000

130,000

'

'

'

'

'

'

'

'

'

'

Interest expense resulting from accretion of the unamortized discount

$283,000

$295,000

'

'

'

'

'

'

'

'

'

'

Capital_Stock_Details

Capital Stock (Details) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Oct. 31, 2012

Jun. 30, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Series A Preferred Stock, $0.001 par value per share

12% Convertible Promissory Note [Member]

8% convertible promissory note [Member]

Convertible promissory notes [Member]

George J Coates [Member]

George J Coates [Member]

George J Coates [Member]

George J Coates [Member]

George J Coates [Member]

Son Of Director [Member]

Son Of Director [Member]

Son Of Director [Member]

Dutchess [Member]

Dutchess [Member]

Dr. Frank J. [Member]

Dr. Frank J. [Member]

Dr. Frank J. [Member]

Dr. Frank J. [Member]

Richard W Evans [Member]

Mutual Agreement [Member]

Mutual Agreement [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Series A Preferred Stock, $0.001 par value per share

Warrant [Member]

Compensatory Stock Awards 2011 [Member]

Compensatory Stock Awards 2011 [Member]

Dr. Frank J. [Member]

Richard W Evans [Member]

Son Of Director [Member]

Son Of Director [Member]

Son Of Director [Member]

Son Of Director [Member]

Capital Stock (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, authorized shares

1,000,000,000

1,000,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock , par value

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock issued

'

'

'

'

'

'

20,895,046

14,142,085

20,275,046

'

'

4,666,666

5,557,375

666,667

3,618,676

2,256,677

'

'

'

'

'

'

'

'

'

'

'

Common Stock Granted

'

'

'

'

'

'

'

'

'

620,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants sold to purchase one share of common stock

'

'

'

'

'

'

'

'

'

'

'

5,666,668

10,839,752

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

0.015

'

'

'

'

'

'

'

'

'

0.015

0.045

0.04

0.12

Proceeds from issuance of common stock

'

$35,000

'

'

'

'

'

'

'

'

'

$125,000

$355,000

'

$156,000

$259,000

$35,000

'

'

'

'

'

'

'

'

'

'

Fair value of common stock issued

'

'

'

'

'

'

1,761,000

430,000

1,674,000

87,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from exercise of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of convertible promissory notes to be issued pursuant to convertible note agreement

'

'

'

335,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount of 12% debt issued one

'

'

'

67,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount of debt 12% issued two

'

'

'

28,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount of12% debt issued three

'

'

'

28,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount of 12% debt issued four

'

'

'

28,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Nominal Interest Rate

'

'

'

'

'

'

'

17.00%

17.00%

'

'

'

'

'

'

'

17.00%

17.00%

17.00%

'

'

'

'

'

'

'

'

Proceeds from issuance of convertible debt

398,000

244,500

'

135,000

208,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount on issuance of convertible promissory notes

'

'

'

16,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common shares issued upon conversion of debt

10,968,349

8,415,515

'

2,750,000

10,968,349

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount of debt, converted into shares of common stock

'

231,768

'

67,000

204,000

305,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

120,000

'

'

'

'

Accrued interest on debt converted into shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,000

'

'

'

'

'

Deferred compensation liability

'

'

'

'

'

'

'

231,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, authorized shares

100,000,000

100,000,000

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of voting rights of peferred stockholder

'

'

'Each share of Series A Preferred Stock entitles the holder of record to the right to vote 10,000 shares of common stock with respect to all matters that are submitted to a vote of shareholders.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of votes from Series A Preferred Stock held

'

'

'

'

'

'

'

'

'

'

'anti-dilution agreement resulting in the right to 685,900,000 aggregate additional votes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of Series A Preferred Stock issued

'

'

'

'

'

'

'

'

'

'

68,590

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of Series A Preferred Stock issued and outstanding

141,473

72,883

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted shares of common stock sold

'

'

'

'

'

8,415,515

'

'

'

'

'

'

190,185

'

'

'

551,281

'

'

240,000

1,100,000

639,939

2,000,000

'

'

'

'

Tradable shares

'

'

'

'

'

'

'

'

'

'

'

'

185,185

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares, Reserved

121,424,724

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional shares of preferred stock

'

'

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

'

'

'

'

'

'

'

'

'

'

$170,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, outstanding shares

327,749,176

305,078,818

'

'

'

'

'

'

18,593,313

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unearned_Revenue_Details

Unearned Revenue (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Unearned Revenue [Abstract]	'	'
Unearned revenue	$19,124	$19,124

Sublicensing_Fee_Revenue_Detai

Sublicensing Fee Revenue (Details) (Sublicensing Fee Revenue [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Sublicensing Fee Revenue [Member]	'	'
Sublicensing Fee Revenue [Line Items]	'	'
Sublicensing fee revenue	$19,000	$19,000
Sublicense deposit received as down payment on Canadian License	$300,000	$300,000
Amortization Method, Description	'Straight-line basis over the approximate remaining life until 2027	'Straight-line basis over the approximate remaining life until 2028.

Other_Income_Details

Other Income (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Other Income (Textual)	'	'
Other Income	'	$60,000
Insurance Settlement [Member]	'	'
Other Income (Textual)	'	'
Other Income	'	50,000
Non Refundable Unearned Income [Member]	'	'
Other Income (Textual)	'	'
Other Income	'	$10,000

Income_Loss_Per_Share_Details

Income (Loss) Per Share (Details) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012
Trading Securities [Abstract]	'		'
Number of underlying shares	45,970,314		36,658,270
Common stock options 1	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	100,000		5,607,000
Exercise Price	0.042		0.06
Number of vested shares	'		'
Number of non - vested shares	100,000		5,607,000
Common stock options 2	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	5,607,000		1,800,000
Exercise Price	0.06		0.24
Number of vested shares	5,607,000		1,800,000
Number of non - vested shares	'		'
Common stock options 3	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	1,800,000		2,000,000
Exercise Price	0.24		0.25
Number of vested shares	1,800,000		2,000,000
Number of non - vested shares	'		'
Common stock options 4	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	2,000,000		50,000
Exercise Price	0.25		0.39
Number of vested shares	2,000,000		50,000
Number of non - vested shares	'		'
Common stock options 5	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	50,000		360,000
Exercise Price	0.39		0.4
Number of vested shares	50,000		360,000
Number of non - vested shares	'		'
Common stock options 6	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	360,000		100,000
Exercise Price	0.4		0.43
Number of vested shares	360,000		100,000
Number of non - vested shares	'		'
Common stock options 7	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	100,000		1,750,000
Exercise Price	0.43		0.44
Number of vested shares	100,000		1,750,000
Number of non - vested shares	'		'
Common stock options 8	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	1,750,000		30,000
Exercise Price	0.44		1
Number of vested shares	1,750,000		30,000
Number of non - vested shares	'		'
Common stock options 9	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	30,000		'
Exercise Price	1		'
Number of vested shares	30,000		'
Number of non - vested shares	'		'
Common stock warrants 1	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	500,000		333,333
Exercise Price	0.02		0.045
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 2	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	666,667		400,000
Exercise Price	0.0225		0.05
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 3	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	1,000,000		2,181,819
Exercise Price	0.025		0.055
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 4	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	333,333		2,000,000
Exercise Price	0.03		0.06
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 5	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	2,000,001		4,269,838
Exercise Price	0.035		0.0625
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 6	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	500,000		571,429
Exercise Price	0.04		0.07
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 7	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	333,333		666,666
Exercise Price	0.045		0.09
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 8	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	400,000		416,667
Exercise Price	0.05		0.12
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 9	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	2,181,819		1,200,000
Exercise Price	0.055		0.25
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 10	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	2,000,000		833,333
Exercise Price	0.06		0.27
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 11	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	4,269,838		333,333
Exercise Price	0.0625		0.3
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 12	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	571,429		153,846
Exercise Price	0.07		0.325
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 13	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	666,666		1,028,570
Exercise Price	0.09		0.35
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 14	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	416,667		'
Exercise Price	0.12		'
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 15	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	1,200,000		'
Exercise Price	0.25		'
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 16	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	833,333		'
Exercise Price	0.27		'
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 17	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	333,333		'
Exercise Price	0.3		'
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 18	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	153,846		'
Exercise Price	0.325		'
Number of vested shares	'		'
Number of non - vested shares	'		'
Common stock warrants 19	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	1,028,570		'
Exercise Price	0.35		'
Number of vested shares	'		'
Number of non - vested shares	'		'
10,000, 10% Convertible promissory note	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	22,222		22,222
Exercise Price	0.45		0.45
Number of vested shares	'		'
Number of non - vested shares	'		'
8% Convertible promissory notes	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	6,445,105		10,550,214
Exercise Price	'	[1]	'	[2]
Number of vested shares	'		'
Number of non - vested shares	'		'
10% Convertible promissory notes	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	3,160,920		'
Exercise Price	'	[1]	'
Number of vested shares	'		'
Number of non - vested shares	'		'
12% Convertible promissory notes	'		'
Trading Securities [Abstract]	'		'
Number of underlying shares	5,156,232		'
Exercise Price	'	[1]	'
Number of vested shares	11,697,000		6,090,000
Number of non - vested shares	100,000		5,607,000
[1]	The principal amount of convertible promissory notes outstanding at December 31, 2013, was $272,000. Under the convertible terms of these notes, the number of share of common stock into which these notes are convertible is variable because the conversion rates of the notes are based on the trading price of the common stock over a defined a number of trading days leading up to the conversion date during a defined conversion rate pricing period. The actual number of shares underlying these convertible instruments will likely vary from the number assumed above. The number of shares underlying these convertible notes was determined based on the defined conversion rates of the various convertible notes, assuming conversion had occurred as of December 31, 2013.
[2]	The principal amount of convertible promissory notes outstanding, none of which were eligible for conversion at December 31, 2012, was $120,000. The conversion rate is variable as it is equal to the average of the three lowest closing bid prices during the ten trading days prior to the date of conversion. The actual number of shares underlying these convertible instruments will likely vary from the number assumed above. The number of shares underlying these convertible notes was determined based on the three lowest closing bid prices during the ten trading days prior to December 31, 2012.

Income_Loss_Per_Share_Details_

Income (Loss) Per Share (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income (Loss) Per Share (Textual)	'	'
Potentially issuable common stock	45,970,314	36,658,270
10,000, 10% Convertible promissory note	'	'
Income (Loss) Per Share (Textual)	'	'
Potentially issuable common stock	22,222	22,222
Promissory notes, interest rate	10.00%	10.00%
Convertible promissory notes outstanding eligible for conversion	10,000	10,000
8% Convertible promissory notes	'	'
Income (Loss) Per Share (Textual)	'	'
Potentially issuable common stock	6,445,105	10,550,214
Promissory notes, interest rate	8.00%	8.00%
Convertible promissory notes outstanding not eligible for conversion	'	120,000
Convertible promissory notes outstanding eligible for conversion	272,000	'
Description of conversion rate of debt	'The conversion rates of the notes are based on the trading price of the common stock over a defined a number of trading days leading up to the conversion date during a defined conversion rate pricing period.	'The conversion rate is variable as it is equal to the average of the three lowest closing bid prices during the ten trading days prior to the date of conversion.
Description of determination of shares underlying convertible notes	'The number of shares underlying these convertible notes was determined based on the defined conversion rates of the various convertible notes, assuming conversion had occurred as of December 31, 2013.	'The number of shares underlying these convertible notes was determined based on the three lowest closing bid prices during the ten trading days prior to December 31, 2012.
10% Convertible promissory notes	'	'
Income (Loss) Per Share (Textual)	'	'
Potentially issuable common stock	3,160,920	'
Promissory notes, interest rate	10.00%	'
Convertible promissory notes outstanding eligible for conversion	272,000	'
Description of conversion rate of debt	'The conversion rates of the notes are based on the trading price of the common stock over a defined a number of trading days leading up to the conversion date during a defined conversion rate pricing period.	'
Description of determination of shares underlying convertible notes	'The number of shares underlying these convertible notes was determined based on the defined conversion rates of the various convertible notes, assuming conversion had occurred as of December 31, 2013.	'
12% Convertible promissory notes	'	'
Income (Loss) Per Share (Textual)	'	'
Potentially issuable common stock	5,156,232	'
Promissory notes, interest rate	12.00%	'
Convertible promissory notes outstanding eligible for conversion	272,000	'
Description of conversion rate of debt	'The conversion rates of the notes are based on the trading price of the common stock over a defined a number of trading days leading up to the conversion date during a defined conversion rate pricing period.	'
Description of determination of shares underlying convertible notes	'The number of shares underlying these convertible notes was determined based on the defined conversion rates of the various convertible notes, assuming conversion had occurred as of December 31, 2013.	'

Stock_Options_Details

Stock Options (Details) (Stock Option [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Summary of common stock options outstanding under Stock Option Plan	'	'
Minimum Exercise Price Per Share, Beginning balance	0.6	0.25
Maximum Exercise Price Per Share, Beginning balance	1	1
Exercise Price Per Share, Vested	0.24	'
Exercise Price Per Share, stock options granted	$0.04	$0.06
Minimum Exercise Price Per Share, Ending balance	0.042	0.6
Maximum Exercise Price Per Share, Ending balance	1	1
Number Outstanding, Beginning balance	11,697,000	6,090,000
Stock option granted, Number Outstanding	100,000	5,607,000
Number Outstanding, Balance	11,797,000	11,697,000
Weighted Average Remaining Contractual Life	'12 years	'12 years
Weighted Average Remaining Contractual Life, Vested	'14 years	'14 years
Weighted Average Remaining Contractual Life, Stock options granted	'15 years	'15 years
Number Exercisable, Beginning balance	6,090,000	2,290,000
Number Exercisable, Vested	5,607,000	3,800,000
Number Exercisable, Balance	11,697,000	6,090,000
Weighted Average Exercise Price, Beginning balance	$0.19	$0.32
Weighted Average Exercise Price, Vested	$0.24	'
Weighted Average Exercise Price, Balance	$0.19	$0.19
Weighted Average Fair Value Per Stock Option at Date of Grant, Beginning balance	$0.18	$0.28
Weighted Average Fair Value Per Stock Option at Date of Grant, Vested	$0.24	$0.24
Weighted Average Fair Value Per Stock Option at Date of Grant, Stock options granted	$0.04	$0.06
Weighted Average Fair Value Per Stock Option at Date of Grant, Balance	$0.18	$0.18
Maximum [Member]	'	'
Summary of common stock options outstanding under Stock Option Plan	'	'
Exercise Price Per Share, Vested	0.24	0.25
Number Exercisable, Vested	5,607,000	2,000,000
Weighted Average Exercise Price, Vested	$0.24	$0.25
Minimum [Member]	'	'
Summary of common stock options outstanding under Stock Option Plan	'	'
Exercise Price Per Share, Vested	0.24	0.24
Number Exercisable, Vested	5,607,000	1,800,000
Weighted Average Exercise Price, Vested	$0.24	$0.24

Stock_Options_Details_1

Stock Options (Details 1)	12 Months Ended
	Dec. 31, 2013
Summary of assumptions used to determine weighted average fair value	'
Historical stock price volatility, minimum	139.00%
Historical stock price volatility, maximum	325.00%
Risk-free interest rate, minimum	0.21%
Risk-free interest rate, maximum	4.64%
Expected life (in years)	'4 years
Dividend yield	0.00%

Stock_Options_Details_2

Stock Options (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013
Company Supplier [Member] | 10/7/2015	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Non-employees	30,000	[1]
Exercise Perice per share	$1
George J Coates [Member] | 10/23/2021	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Employees	1,000,000	[1]
Exercise Perice per share	$0.44
George J Coates [Member] | 11/4/2024	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Employees	50,000	[1]
Exercise Perice per share	$0.43
George J Coates [Member] | 11/17/2025	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Employees	275,000	[1]
Exercise Perice per share	$0.40
George J Coates [Member] | 7/25/2026	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Employees	1,800,000	[1]
Exercise Perice per share	$0.25
George J Coates [Member] | 6/24/2027	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Employees	1,815,000	[1]
Exercise Perice per share	$0.06
Gregory Coates [Member] | 10/23/2021	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Employees	500,000	[1]
Exercise Perice per share	$0.44
Gregory Coates [Member] | 8/8/2026	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Employees	1,800,000	[1]
Exercise Perice per share	$0.24
Barry C. Kaye [Member] | 10/18/2021	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Employees	125,000	[1]
Exercise Perice per share	$0.44
Barry C. Kaye [Member] | 12/11/2028	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Employees	100,000	[2]
Exercise Perice per share	$0.04
Dr. Frank J. [Member] | 3/28/2022	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Non-employees	25,000	[1]
Exercise Perice per share	$0.44
Dr. Frank J. [Member] | 11/3/2024	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Non-employees	50,000	[1]
Exercise Perice per share	$0.43
Dr. Frank J. [Member] | 11/17/2025	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Non-employees	85,000	[1]
Exercise Perice per share	$0.40
Dr. Frank J. [Member] | 6/24/2027	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Non-employees	667,000	[1]
Exercise Perice per share	$0.06
Richard W Evans [Member] | 3/28/2022	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Non-employees	25,000	[1]
Exercise Perice per share	$0.44
Richard W Evans [Member] | 12/27/2024	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Non-employees	50,000	[1]
Exercise Perice per share	$0.39
Richard W Evans [Member] | 2/15/2026	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Non-employees	200,000	[1]
Exercise Perice per share	$0.25
Richard W Evans [Member] | 6/20/2027	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Non-employees	3,125,000	[1]
Exercise Perice per share	$0.06
Dr. Michael J. Suchar [Member] | 3/28/2022	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Non-employees	25,000	[1]
Exercise Perice per share	$0.44
Richard Whitworth [Member] | 3/28/2022	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Non-employees	25,000	[1]
Exercise Perice per share	$0.44
William Wolf. Esq. [Member] | 4/4/2022	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of Shares of Common Stock Underlying Stock Options, Non-employees	25,000	[1]
Exercise Perice per share	$0.44
[1]	These stock options are fully vested.
[2]	These options will fully vest in December 2014.

Stock_Options_Details_Textual

Stock Options (Details Textual) (USD $)	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jun. 30, 2012	Jun. 30, 2012	Jun. 30, 2012
		2006 Stock Option and Incentive Plan [Member]	2006 Stock Option and Incentive Plan [Member]	2006 Stock Option and Incentive Plan [Member]	2006 Stock Option and Incentive Plan [Member]	2006 Stock Option and Incentive Plan [Member]	2006 Stock Option and Incentive Plan [Member]
				Barry C. Kaye [Member]	Dr. Richard W. Evans [Member]	George J Coates [Member]	Dr. Frank J. Adipietro [Member]
Stock Options (Textual)	'	'	'	'	'	'	'
Stock option granted, Number Outstanding	'	'	5,607,000	'	'	'	'
Maximum percentage of shares issuable in one year to one employee	'	25.00%	'	'	'	'	'
Maximum number of shares of common stock authorized for issue under plan	'	12,500,000	'	'	'	'	'
Stock options granted during period	'	100,000	'	'	3,125,000	1,815,000	667,000
Stock option granted during period, exercise price	'	'	'	$0.04	$0.06	$0.06	$0.06
Non-cash stock-based compensation expense related to employee stock options	'	$179,000	$714,000	'	'	'	'
Stock option expense included in general and administrative expenses	'	15,000	229,000	'	'	'	'
Stock option expense included in research and development expenses	'	164,000	485,000	'	'	'	'
Options expired date, Discription	'	'Options become vested in December 2014 and expire in December 2028.	'Options became fully vested June 2013 and expire June 2027.	'	'	'	'
Estimated fair value of stock options vested	'	358,000	917,000	'	'	'	'
Estimated fair value of stock options granted	'	4,000	358,000	'	'	'	'
Compensation cost related to nonvested stock options	$4,000	$4,000	'	'	'	'	'

Investment_Agreement_with_Dutc1

Investment Agreement with Dutchess Opportunity Fund II, L.P. (Details) (USD $)	1 Months Ended	12 Months Ended
	Jun. 30, 2011	Dec. 31, 2013	Dec. 31, 2012
Investment Agreement with Dutchess Opportunity Fund II, L.P. (Textual)	'	'	'
Purchase commitment terms	'36 months	'	'
Number of common stock registered for resale	17,500,000	'	'
Investment agreement terms	'	'Equal to, at its option, either (i) two hundred percent (200%) of the average daily volume (U.S. market only) of its common stock for the three (3) Trading Days prior to the applicable Put Notice Date, multiplied by the average of the three (3) daily closing prices immediately preceding the Put Date or (ii) (x) the lesser of the value of the unsold registered shares under the equity line of credit based on the closing price of the common stock on the day prior to the Put Notice, or (y) five hundred thousand dollars ($500,000).	'
Description of put option purchase price	'	'Equal to ninety-four percent (94%) of the lowest daily volume weighted average prices of the common stock during the period beginning on the Put Notice Date and ending on and including the date that is five (5) trading days after such Put Notice Date (the "Pricing Period").	'
Number of common stock sold	'	3,618,676	2,256,677
Proceeds from common stock sold under equity line of credit	'	$156,000	$259,000
Number of unsold registered shares of common stock	'	11,614,647	'

Placement_Agency_Agreement_wit1

Placement Agency Agreement with Stonegate Securities, Inc. (Details) (Stonegate Securities Inc [Member])	12 Months Ended
	Dec. 31, 2013
Stonegate Securities Inc [Member]	'
Placement Agency Agreement with Stonegate Securities, Inc. (Textual)	'
Placement agency agreement term	'The term of the agreement shall continue until cancelled by either party upon ten (10) days written notice.
Percentage of service fee of gross proceeds from sale of securities	8.00%
Placement closing terms description	'Upon closing of a Placement, the Company is required to issue to Stonegate restricted shares of common stock of the Company in an amount equal to two percent (2%) of the total number of shares of common stock sold, and/or in the event of a sale of convertible securities, the number of shares of common stock that would be potentially received upon a conversion of any convertible securities sold in the Placement.
Number of shares that were issued upon execution of agreement	200,000
Maximum percentage of gross proceeds for reimbursement of expenses	1.00%

Income_Taxes_Details

Income Taxes (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Schedule of total deferred tax assets and valuation allowances	'	'
Current deferred tax asset - inventory reserve	$195,000	$195,000
Non-Current Deferred Tax Assets:	'	'
Net operating loss carryforwards	6,201,000	5,774,000
Stock-based compensation expense	1,688,000	1,436,000
Accrued liabilities not paid	481,000	492,000
Deferred compensation not paid within 2.5 months	115,000	'
Accrued interest on notes to related parties	115,000	64,000
Total long-term deferred tax assets	8,600,000	7,766,000
Total deferred tax assets	8,795,000	7,961,000
Less: valuation allowance	-8,795,000	-7,961,000
Net deferred tax assets	'	'

Income_Taxes_Details_1

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Schedule of differences in Income tax (benefit) provision	'	'
Federal tax provision (benefit) at the statutory rate	34.00%	34.00%
State income tax provision (benefit), net of federal benefit	-2.70%	-2.70%
Net change in net operating loss carryforwards	-15.50%	-16.60%
Stock-based compensation expense	-9.10%	-15.60%
Accrued interest not deductible for tax return purposes	-6.00%	-1.20%
Deferred compensation not paid within 2.5 months	-4.20%	'
(Increase) Decrease in estimated fair value of embedded derivative liabilities	-3.10%	2.90%
Provision for slow-moving and obsolete inventory	'	-2.10%
Accrued liabilities not deductible for tax return purposes	0.40%	-1.10%
Officer's life insurance	-0.20%	'
Total	-6.40%	-2.40%
Valuation allowance	6.40%	2.40%
Effective tax rate	0.00%	0.00%

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Taxes (Textual)	'	'
Federal tax provision (benefit) at the statutory rate	34.00%	34.00%
Increase in deferred tax assets	$834,000	$1,470,000
Federal [Member]	'	'
Income Taxes (Textual)	'	'
Operating loss carryforwards	16,677,000	'
Operating loss carryforwards expiration date description	'Expiring between 2018 and 2032.	'
New Jersey [Member]	'	'
Income Taxes (Textual)	'	'
Operating loss carryforwards	$7,835,000	'
Operating loss carryforwards expiration date description	'Expiring between 2014 and 2033.	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012
George J Coates [Member]	'		'
Summary of approximate amount of base compensation and benefits	'		'
Base compensation and benefits	$29,000	[1],[2],[3],[4],[5],[6],[7]	$277,000	[1],[2],[3],[4],[5],[6],[7]
Gregory Coates [Member]	'		'
Summary of approximate amount of base compensation and benefits	'		'
Base compensation and benefits	169,000	[1]	173,000	[1],[8]
Bernadette Coates [Member]	'		'
Summary of approximate amount of base compensation and benefits	'		'
Base compensation and benefits	$15,000	[9]	$77,000	[9]
[1]	Includes compensation paid in 2012 for vacation earned but not taken.
[2]	For the year ended December 31, 2013, George J. Coates earned additional base compensation of $231,000, payment of which is being deferred until the Company has sufficient working capital. This amount is included in deferred compensation in the accompanying balance sheet at December 31, 2013.
[3]	During the year ended December 31, 2013, George J. Coates was awarded 14,142,085 unregistered shares of the Company's common stock for anti-dilution protection related to new shares of common stock issued in 2013. The estimated value of these shares, based on the closing trading price of the stock on the dates of issuance was $430,000 which was charged to stock-based compensation expense for the the year ended December 31, 2013. On August 30, 2013, these shares were voluntarily returned to the Company for cancellation, upon which the shares were restored to the authorized, but unissued status.
[4]	In January 2013, the Company issued 20,895,046 unregistered shares of its common stock to George J. Coates in satisfaction of a deferred compensation liability consisting of 20,275,046 shares for anti-dilution protection for the year ended December 31, 2012 and a 620,000 share stock award originally granted in 2011. The value of these shares, based on the closing trading price on the dates of the anti-dilution or the date of the stock award was $1,761,000, of which $1,674,000 and $87,000 was charged to stock-based compensation expense during the years ended December 31, 2012 and 2011, respectively. On August 30, 2013, these shares were voluntarily returned to the Company for cancellation, upon which the shares were restored to the authorized, but unissued status.
[5]	During the year ended December 31, 2013, George J. Coates was awarded 68,590 unregistered shares of the Company's Series A Preferred Stock for anti-dilution protection related to new shares of common stock issued in 2013. The estimated value of these shares was $170,000.
[6]	Excludes compensation in 2012 consisting of 20,275,046 restricted shares of common stock awarded to George J. Coates pursuant to an anti-dilution arrangement in effect during the year ended December 31, 2012. Of this amount, 18,593,313 shares of common stock were initially issued throughout 2012. In December 2012, these shares were cancelled and restored to unissued status. The entire 20,275,046 shares of common stock awarded in 2012 were then reissued in January 2013. The estimated fair value of these shares was $1,674,000, which amount is included in stock-based compensation expense in the accompanying statement of operations for the year ended December 31, 2012.
[7]	Excluded from the amounts reported above for 2012 are 1,815,000 stock options with an exercise price of $0.06 per share. The estimated fair value of these stock options on the date of grant was $116,000.
[8]	During the year ended December 31, 2012, the Company recorded stock-based compensation expense amounting to $252,000 in connection with employee stock options granted to Gregory Coates in 2011.
[9]	For the year ended December 31, 2013, Bernadette Coates earned additional base compensation of $57,000, payment of which is being deferred until the Company has sufficient working capital. This amount is included in deferred compensation in the accompanying balance sheet at December 31, 2013.

Related_Party_Transactions_Det1

Related Party Transactions (Details Textual) (USD $)	1 Months Ended	12 Months Ended
	Jan. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Related Party Transactions (Textual)	'	'	'	'
Rate of interest on promissory notes to related parties, compounded monthly	'	17.00%	'	'
Promissory notes unpaid accrued interest	'	$230,000	'	'
Common stock, outstanding shares	'	327,749,176	305,078,818	'
George J Coates [Member]	'	'	'	'
Related Party Transactions (Textual)	'	'	'	'
Shares of common stock issued	20,895,046	14,142,085	20,275,046	'
Fair value of common stock issued	1,761,000	430,000	1,674,000	87,000
Deferred compensation liability	'	231,000	'	'
Common stock, outstanding shares	'	'	18,593,313	'
Options outstanding	'	'	1,815,000	'
Exercise price of options	'	'	$0.06	'
Options intrinsic value	'	'	116,000	'
Restricted shares of common stock award	'	'	20,275,046	'
Shares of common stock initially issued	'	'	18,593,313	'
Estimated fair value	'	'	1,674,000	'
George J Coates [Member] | Series A Preferred Stock [Member]	'	'	'	'
Related Party Transactions (Textual)	'	'	'	'
Shares of Series A Preferred Stock issued	'	68,590	'	'
Fair value of Series A Preferred Stock issued	'	170,000	'	'
Gregory Coates [Member]	'	'	'	'
Related Party Transactions (Textual)	'	'	'	'
Compensation expense related to stock options granted in 2011	'	'	252,000	'
Bernadette Coates [Member]	'	'	'	'
Related Party Transactions (Textual)	'	'	'	'
Deferred compensation liability	'	57,000	'	'
Barry C. Kaye [Member]	'	'	'	'
Related Party Transactions (Textual)	'	'	'	'
Deferred compensation liability	'	120,000	'	'
Compensation paid	'	$40,000	$67,000	'

Contractual_Obligations_and_Co2

Contractual Obligations and Commitments (Details) (USD $)	Dec. 31, 2013
Summary of Company's contractual obligations	'
Due Within 2014	$2,523,000
Due Within 2015	82,000
Due Within 2016	22,000
Total	2,627,000
Mortgage loan payable [Member]	'
Summary of Company's contractual obligations	'
Due Within 2014	1,513,000
Due Within 2015	'
Due Within 2016	'
Total	1,513,000
Promissory notes to related parties [Member]	'
Summary of Company's contractual obligations	'
Due Within 2014	603,000
Due Within 2015	'
Due Within 2016	'
Total	603,000
Convertible promissory notes [Member]	'
Summary of Company's contractual obligations	'
Due Within 2014	272,000
Due Within 2015	'
Due Within 2016	'
Total	272,000
Finance lease obligation [Member]	'
Summary of Company's contractual obligations	'
Due Within 2014	50,000
Due Within 2015	72,000
Due Within 2016	22,000
Total	144,000
Settlement of litigation [Member]	'
Summary of Company's contractual obligations	'
Due Within 2014	75,000
Due Within 2015	10,000
Due Within 2016	'
Total	85,000
10% promissory note [Member]	'
Summary of Company's contractual obligations	'
Due Within 2014	10,000
Due Within 2015	'
Due Within 2016	'
Total	$10,000

Contractual_Obligations_and_Co3

Contractual Obligations and Commitments (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013
Contractual Obligations And Commitments [Line Items]	'
Compensation cost related to nonvested stock options	$4,000
Recognition period for compensation expense	'11 months

Litigation_and_Contingencies_D

Litigation and Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Litigation And Contingencies Textual [Abstract]	'
Litigation settlement first installment amount, due on November 28, 2013	$40,000
Litigation settlement second installment amount, due on the 15th day of March 2014	25,000
Litigation settlement third installment amount, due on the 15th day of June 2014	25,000
Litigation settlement fourth installment amount, due on the 15th day of September 2014	25,000
Litigation settlement fifth installment amount, due on the 15th day of February 2015	10,000
Litigation settlement total amount	125,000
Accrued compensation included in accounts payable and accrued liabilities	85,000
Total amount to be paid in the event of default	$200,000

Subsequent_Events_Details

Subsequent Events (Details) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jan. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jan. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Series A Preferred Stock [Member]

George J Coates [Member]

George J Coates [Member]

George J Coates [Member]

George J Coates [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Series B Convertible Preferred Stock [Member]

Barry C. Kaye [Member]

George J Coates [Member]

George J Coates [Member]

Bernadette Coates [Member]

Richard W Evans [Member]

Convertible Promissory Note [Member]

Convertible Promissory Note [Member]

12% Convertible Promissory Note [Member]

8 % Convertible Note [Member]

17% Promissory Note [Member]

17% Promissory Note [Member]

Series A Preferred Stock [Member]

George J Coates [Member]

Bernadette Coates [Member]

Subsequent Events (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of unregistered restricted shares of common stock

'

'

'

'

'

'

'

7,339,286

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of warrants to purchase restricted common stock

'

'

'

'

'

'

'

6,625,000

'

'

'

'

'

714,286

'

'

'

'

'

'

Exercise price of warrants

'

'

'

'

'

'

'

0.04

'

'

'

'

'

0.035

'

'

'

'

'

'

Proceeds from issuance of common stock and warrants

$281,000

$649,000

'

'

'

'

'

'

'

'

'

'

'

$290,000

'

'

'

'

'

'

Principal Amount

272,000

120,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturity date, description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'mature on the one year anniversary of the notes.

'

'

'

'

Proceeds from issuance of promissory note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33,333

'

'

'

'

'

Debt Instrument, Payment Terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The promissory note may be prepaid at any time within the first 180 days with a 30% prepayment penalty. The lender may convert the promissory notes into shares of the Company's common stock at any time beginning 180 days after the date of funding. The conversion rate shall be equal to the lesser of $0.05 per share or 70% of the lowest trade price of the common stock during the 20 consecutive trading days prior to the date of conversion.

'

'

'

'

'

Monthly payments of interest, plus $5,000 which is being applied to the principal balance.

Number of shares reserved for potential conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,500,000

'

'

'

'

Shares of common stock reserved for conversion of note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,050,000

2,059,138

'

'

Additional deferred compensation

'

'

'

'

'

'

'

'

'

10,000

58,000

'

16,000

'

'

'

'

'

'

'

Total deferred compensation

'

'

'

'

'

'

'

'

'

130,000

228,000

'

72,000

'

'

'

'

'

'

'

Principal amount of debt, converted into shares of common stock

'

231,768

'

'

'

'

'

'

'

'

'

'

'

'

'

'

58,000

55,000

'

'

Repayment of promissory notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,000

15,000

Registered shares of common stock issued under equity line of credit

'

'

'

'

'

'

'

2,561,713

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from common stock issued under equity line of credit

'

'

'

'

'

'

'

102,000

'

'

'

'

'

'

'

'

'

'

'

'

Shares of Series a Preferred Stock issued

'

'

'

20,895,046

14,142,085

20,275,046

'

'

'

'

'

20,708

'

'

'

'

'

'

'

'

Fair value of Series a Preferred Stock issued

'

'

'

$1,761,000

$430,000

$1,674,000

$87,000

'

'

'

'

$52,000

'

'

'

'

'

'

'

'

Preferred stock, authorized shares

100,000,000

100,000,000

1,000,000

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value

$0.00

$0.00

$0.00

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'